[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endometrial-neoplasms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endometrial-neoplasms":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,27,0,25,[9,47,77,98,137,168,207,232,264,300,349,383,408,449,474,490,508,538,569,589,617,642,666,690,716],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100573826","phase-1-a-study-of-dm002-in-patients-with-advanced-solid-tumors-100573826",false,"NCT06751329","A Study of DM002 in Patients With Advanced Solid Tumors","A Phase I\u002FIIa, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\nCommon Inclusion Criteria (Part 1 and Part 2)\n\n1. Subjects must have the ability to understand and willingness to sign a written informed consent document.\n2. Subjects must be ≥18 years of age at the time of signing the informed consent form.\n3. Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.\n4. Has a life expectancy of ≥3 months.\n5. Participants must meet the following laboratory values within 7 days prior to first dose of study drug:\n\n   Note: Transfusion (red blood cell or platelet) or granulocyte-colony stimulating factor (G-CSF) administration is not allowed within 2 weeks prior to laboratory assessments at Screening.\n   * Absolute neutrophil count (ANC) ≥1.5 × 10⁹\u002FL;\n   * Platelet count ≥100 × 10⁹\u002FL;\n   * Hemoglobin ≥9 g\u002FdL;\n   * Calculated creatinine clearance (CrCL) \\>60 mL\u002Fmin (Cockroft-Gault Equation);\n   * Total bilirubin ≤ 1.5 x ULN;\n   * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0 × upper limit of normal (ULN), if liver metastases are present, ≤5 × ULN;\n   * International normalized ratio (INR)\\\u003C2.0, and prothrombin time and either partial thromboplastin time (PTT) or activated PTT (aPTT) ≤1.5 × ULN, except for participants receiving anti-vitamin K derivative anticoagulant therapy who must have prothrombin time\u002FINR within therapeutic range as deemed appropriate by the Investigator.\n6. Has measurable disease based on RECIST version 1.1.\n7. Participants are required to provide tumor tissue specimens obtained within the previous 3 years for the measurement of MUC1 and\u002For HER3 and other biomarkers. For those subjects who are unable to provide tissue samples will be encouraged (but not mandatory) to undergo biopsy if the risk is manageable. If the biopsy is not possible, it should inform the sponsor for enrolment.\n\nExclusion Criteria:\n\n1. Subjects have another active invasive malignancy within 5 years, with the following exceptions and notes:\n\n   1. History of noninvasive malignancy, such as cervical cancer in situ, in situ melanoma, or ductal carcinoma in situ of the breast that is in complete remission 5 years after treatment with curative intent is allowed.\n   2. Malignancies with a negligible risk of metastasis or death (such as adequately treated basal or squamous cell skin cancer and localized prostate cancer).\n2. Current or history of a hematologic malignancy.\n3. Anticancer therapy (chemotherapy, immunotherapy, hormonal therapy, targeted therapy, biologic therapy, or other anti-cancer therapies, except for hormones for hypothyroidism or estrogen replacement therapy, anti-estrogen analogs, agonists required to suppress serum testosterone levels) within 28 days or 5 half-lives, whichever is shorter, prior to the first study dose. Radiotherapy with a wide field of radiation within 28 days, or radiotherapy with a limited field of radiation for palliation within 14 days of the first study dose. Major surgery, other than diagnostic surgery, within 4 weeks of the first study dose.\n4. Primary central nervous system (CNS) malignancies or CNS metastases. Individuals with brain metastases can be enrolled only if treated, nonprogressive brain metastases and off high-dose steroids (\\>20 mg prednisone or equivalent) for at least 4 weeks.\n5. History of known allergies to ADC, or prior discontinuation of an ADC due to treatment-related toxicities. Has received prior treatment with ADCs that include topoisomerase I (Topo I) payload, and treatment history with any investigational drug within 4 weeks before enrolment in the study.\n6. Has an uncontrolled infection requiring IV injection of antibiotics, antivirals, or antifungals.\n7. Has a pre-existing clinically significant lung diseases (e.g., interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) or pre-existing ocular disorders.\n8. Clinically uncontrolled intercurrent illness, including but not limited to an ongoing active infection, active coagulopathy, uncontrolled cardiovascular disease, uncontrolled immune disease, uncontrolled diabetes, uncontrolled pleural and peritoneal effusion, psychiatric illness that would limit compliance with the study requirements and other serious medical illnesses requiring systemic therapies.\n9. Mean resting corrected QT interval corrected by Fridericia's formula (QTcF) \\>470 msec obtained from triplicate 12-lead ECGs at baseline; using concomitant medications that would prolong the QT interval.\n10. Left ventricular ejection fraction \\\u003C50% by either an echocardiogram (ECHO) or a multi-gated acquisition scan within 28 days before first dose of the study drug.\n11. Known active hepatitis B (HBV) or hepatitis C (HCV) infection. Chronic carriers of HBV infection (HBsAg-positive, undetectable HBV DNA or HBV DNA ≤2500 copies\u002Fml or 500 IU\u002Fml) receive prophylactic treatment during the study can be enrolled. Participants with a history of HCV infection have completed curative antiviral treatment and HCV viral load below the limit of quantification and HCV antibody positive but HCV ribonucleic acid (RNA) negative due to prior treatment or natural resolution should be eligible.\n12. Known human immunodeficiency virus (HIV) infection which is not well controlled. Participants should be tested for HIV prior to enrollment if required by local regulations or institutional review board (IRB)\u002Fethics committee. All the following criteria are required to define an HIV infection (positive HIV1\u002F2 antibodies test) that is well controlled: HIV viral load \\\u003C400 copies\u002FmL, CD4+ T- cell counts ≥350 cells\u002FμL, no history of acquired immunodeficiency syndrome-defining opportunistic infection within the past 12 months, and stable viral load for at least 4 weeks on same anti-HIV retroviral medications.\n13. Subjects who are from endemic areas (refer to WHO high tuberculosis burden country list, China is endemic area) will be specifically screened for tuberculosis with any available test. Subjects with active tuberculosis are excluded. Subjects who have received bacille Calmette-Guerin vaccination may have a false positive result of purified-protein derivative (PPD) test. These subjects are eligible if they have a negative result of interferon gamma release assay (IGRA).\n14. Has received a live vaccine within 30 days prior to the first dose of study drug.\n15. Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia and anemia) not yet resolved to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0, ≤Grade 1 or baseline. Note: Participants may be enrolled with chronic, stable Grade 2 toxicities (defined as no worsening to \\>Grade 2 for at least 3 months prior to enrolment\u002Frandomization and managed with the standard treatment) that the Investigator deems related to previous anticancer therapy, following discussion with the Sponsor's medical monitor, such as the following: Grade 2 chemotherapy-induced neuropathy, hypothyroidism, hyperglycemia.\n16. Females who are pregnant or lactating or who intend to become pregnant during participation in the study are not eligible to participate.\n17. Participants who are of reproductive potential refuse to use effective methods of birth control during participation of the study and within 7 months for female (and 4 months for male) after the last dose administration.\n18. Participants who took drugs or food which can strongly inhibit or induce the cytochrome P450 (CYP) isoenzyme, CYP3A4\u002F5 within 2 weeks prior to the first dose of DM002 or within 5 half-lives, whichever is longer.","ALL","18 Years",{"count":20,"type":21},280,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","The goal of study：\n\nThe study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion.\n\nIn Part 1, a few participants will receive the lowest dose of study drug. The study team will make sure it is safe and tolerated before enrolling new participants at a higher dose of study drug. There will be up to six or more dose levels of study drug tested (called cohorts). Which dose you receive will depend on how many participants have taken part in the study before you.\n\nThe purpose of Part 1 of the study is to evaluate the safety of the study drug at different dose levels, to understand what your body does to the study drug, and to find the best dose of study drug in people who have advanced solid tumor cancers.\n\nIn Part 2, participants will receive the best dose level that was determined in Part 1 of the study.\n\nThe purpose of Part 2 of the study is to evaluate the safety of the study drug at the dose level determined in Part 1, to understand what your body does to the study drug, and to see how your cancer responds to the study drug.\n\nParticipants will:\n\nParticipants will have 17 or more visits to the study centre. This study has a screening phase of up to 28 days , and a treatment phase with cycles of 21 days each. Participants will also have an End of Treatment (EOT) visit 21 days after the final study drug treatment, and a Follow-up visit 30 days after the EOT visit . Participants will be contacted by telephone every 3 months after the Follow-up visit to check on the wellbeing and record any new anticancer therapy they may have started.",[28,29,30,31,32,33],"Ovarian Neoplasms","Prostatic Neoplasms","Endometrial Neoplasms","Colorectal Neoplasms","Solid Carcinoma","Pancreatic Cancer","RECRUITING","2026-07-01",{"date":37,"type":38},"2026-07-02","ACTUAL",{"date":40,"type":38},"2025-02-17",{"date":42,"type":21},"2028-04-18",{"name":44,"class":45},"Xadcera Biopharmaceutical (Suzhou) Co., Ltd.","INDUSTRY",5,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":65,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100601754","phase-1-a-study-of-ly4257496-in-participants-with-cancer-omniray-100601754","NCT07114601","A Study of LY4257496 in Participants With Cancer (OMNIRAY)","A Phase 1a\u002Fb Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults With GRPR-Positive Advanced Solid Tumors (OMNIRAY)","OMNIRAY","Inclusion Criteria:\n\n* Must have histologically or cytologically proven diagnosis of locally advanced, unresectable, or metastatic cancer.\n* Must be assessed by computed tomography (CT)\u002Fmagnetic resonance imaging (MRI) to confirm at least 1 of the following:\n\n  * At least 1 measurable target lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\n  * If only bone lesions are present without a soft-tissue component, a bone scan or MRI must confirm at least 2 detectable lesions considered to represent active metastases\n* Must have GRPR-positive disease, defined by investigator assessment of GRPR imaging.\n* Must have the following histologically or cytologically confirmed diagnosis:\n\n  * Estrogen receptor (ER+)\u002Fhuman epidermal growth factor receptor 2 (HER2-) breast cancer\n  * ER+\u002FHER2+ breast cancer\n  * Esophageal squamous cell carcinoma\n  * Adenocarcinoma of the stomach, gastroesophageal junction, or esophagus\n  * Colorectal carcinoma\n  * Metastatic castration-resistant prostate cancer\n  * Endometrial carcinoma. Carcinosarcoma is eligible. Uterine leiomyosarcoma, adenosarcoma, or endometrial stromal sarcoma is not eligible.\n  * Low-grade papillary serous ovarian cancer\n  * Other non-Central Nervous System (CNS) primary GRPR-positive solid tumors (Cohorts A1 dose escalation and D1 dose expansion only)\n* For participants with breast cancer diagnosis, where possible, ER and HER2 status should be assessed from the most recent tissue biopsy taken at the time of presentation with recurrent or metastatic disease.\n\n  * To fulfill the requirement for ER+ disease by local testing, a tumor must express the ER immunohistochemistry, as defined in the relevant American Society of Clinical Oncology (ASCO)\u002FCollege of American Pathologists (CAP) guidelines.\n  * HER2 status should be determined by local testing, as defined in the relevant ASCO\u002FCAP Guidelines.\n* Must have an Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 1.\n* Must be able to comply with outpatient treatment, laboratory monitoring, imaging, and required clinic visits for the duration of trial participation.\n\nExclusion Criteria:\n\n* Phase 1a (Cohort A1 and A2) only: Previously received radiopharmaceutical or radioligand therapy. For participants with prostate cancer, prior ¹⁷⁷Lu-prostate-specific membrane antigen (PSMA) is permitted.\n* Has a history of ongoing acute pancreatitis within 1 year of screening.\n* Previously received any prior hemi-body or whole-body radiotherapy, or prior external beam radiation therapy (EBRT) to greater than 25% of the bone marrow.\n* A bone superscan, defined as a bone scan that demonstrates markedly increased skeletal radioisotope uptake relative to soft tissues in association with absent or faint genitourinary tract activity.\n* Has evidence of ongoing and untreated urinary tract obstruction or unmanageable urinary incontinence.\n* Have known active hepatitis B virus (HBV). Exception: Individuals with chronic HBV if they:\n\n  * Have positive HBsAg\n  * Are on suppressive antiviral therapy, as allowed per local regulations prior to C1D1\n  * Remain on the same antiviral treatment throughout study, and should follow local standards for continuation of therapy after completion of trial therapy.\n  * Have undetectable HBV DNA ≤14 days of C1D1.\n* Have known active hepatitis C virus (HCV). Exception: Individuals previously treated for HCV if they:\n\n  * Completed curative antiviral therapy.\n  * Have an HCV viral load below the limit of quantification ≤14 days of C1D1 and.\n  * Are positive for anti-HCV antibodies and negative for HCV ribonucleic acid (RNA) before randomization.\n* Have untreated human immunodeficiency virus (HIV) infection. Exception: Individuals who have well-controlled HIV infection\u002Fdisease and they:\n\n  * Are on a stable and permitted antiretroviral therapy (ART) regimen without changes in drug or dose, for at least 4 weeks prior to C1D1\n  * Have a viral load of \\\u003C400 copies\u002FmL ≤14 days of C1D1.\n  * Have a CD4+ T-cell count ≥350 cells\u002FmL ≤14 days of C1D1.\n  * Have not had an opportunistic infection within the past 12 months.\n* Has an active second malignancy unless in remission with life expectancy greater than 2 years.\n* Has known hypersensitivity to any component or excipient of LY4257496.",{"count":56,"type":21},421,[24],"The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive advanced cancer, including but not limited to breast, colorectal, prostate, endometrial, esophageal, gastroesophageal (GE) junction, and gastric cancer. The study will also evaluate the safety, tolerability, and efficacy of LY4257529 to identify cancer with high levels of a protein called GRPR. This is a 2-part study. Participation could last up to 36 weeks or until your tumor progresses.",[60,31,61,30,62,63,64],"Breast Neoplasms","Prostate Neoplasm","Neoplasm Metastasis","Stomach Neoplasms","Esophageal Neoplasms",[66],"GRPR-positive","2026-06-19",{"date":69,"type":38},"2026-06-23",{"date":71,"type":38},"2025-08-06",{"date":73,"type":21},"2035-04",{"name":75,"class":45},"Eli Lilly and Company",32,{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":5},"100596550","phase-1-a-study-of-ly4175408-in-participants-with-advanced-cancer-100596550","NCT07046923","A Study of LY4175408 in Participants With Advanced Cancer","A First-in-Human, Phase 1a\u002F1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4175408, an Antibody Drug Conjugate Targeting Protein Tyrosine Kinase 7-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors","Inclusion Criteria:\n\n* Have one of the following advanced or metastatic solid tumor cancers:\n\n  * Non-small cell lung cancer (NSCLC)\n  * Small cell lung cancer (SCLC)\n  * Endometrial cancer\n  * Triple negative breast cancer (TNBC) (characterized by HR-negative disease and HER2-negative expression according to American Society of Clinical Oncology (ASCO) - College of American Pathologists guidelines).\n* Received all standard therapies for which the individual was deemed to be an appropriate candidate by the treating investigator (except in Cohort B1 and B2 expansion, which require participants who are treatment naive in the advanced metastatic setting); OR the individual is refusing the remaining most appropriate standard of care treatment; OR there is no standard therapy available for the disease.\n* Eastern Cooperative Oncology Group (ECOG) performance status of greater than or equal to (≤) 1.\n* For dose optimization\u002Fdose and expansion cohorts (Cohort A2, Cohort B\u002FC): Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n* Cohorts B1\u002FB2: NSCLC with no known actionable genomic alterations. ≤2 prior lines of systemic therapy for advanced or metastatic disease in safety lead-in; no prior systemic therapy in expansion\n\nExclusion Criteria:\n\n* Prior treatment with a protein tyrosine kinase 7 (PTK7) antibody-drug conjugate (ADC) with a topoisomerase I inhibitor as payload (prior therapy with a PTK7 ADC with a non-topoisomerase I inhibitor payload OR non-PTK7 ADC with any payload is permitted). Prior topoisomerase I-based ADCs are not allowed in cohorts A2, B1 or B2.\n* Any serious unresolved toxicities from prior therapy.\n* Individual with known or suspected history of uncontrolled central nervous system (CNS) metastases.\n* Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection.\n* Significant cardiovascular disease.\n* Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) \\> 470 milliseconds (ms)\n* History of pneumonitis\u002Finterstitial lung disease.\n* Individuals who are pregnant, breastfeeding, or plan to breastfeed during the trial or within 30 days of the last dose of trial intervention.",{"count":85,"type":21},240,[24],"The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could last up to 4 years.",[89,90,30,62,91],"Carcinoma, Non-Small-Cell Lung","Small Cell Lung Carcinoma","Triple Negative Breast Cancer",{"date":69,"type":38},{"date":94,"type":38},"2025-07-28",{"date":96,"type":21},"2030-07",{"name":75,"class":45},{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":108,"conditions":109,"keywords":113,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},"100546861","phase-1-a-study-of-ly4170156-in-participants-with-selected-advanced-solid-tumors-100546861","NCT06400472","A Study of LY4170156 in Participants With Selected Advanced Solid Tumors","A First-in-Human, Phase 1a\u002F1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors","Inclusion Criteria:\n\n* Have one of the following solid tumor cancers:\n\n  * Dose Escalation: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) cancer, endometrial cancer, cervical cancer, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), pancreatic cancer, or colorectal cancer (CRC)\n  * Dose Optimization: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) and endometrial cancer\n  * Dose Expansion: Low grade serous ovarian cancer, cervical cancer, NSCLC, and TNBC\n\nExclusion Criteria:\n\n* Individual with known or suspected uncontrolled central nervous system (CNS) metastases\n* Individual with history of carcinomatous meningitis\n* Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection\n* Individual with evidence of corneal keratopathy or history of corneal transplant\n* Any serious unresolved toxicities from prior therapy\n* Significant cardiovascular disease\n* Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms)\n* History of pneumonitis\u002Finterstitial lung disease\n* Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention",{"count":106,"type":21},495,[24],"The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.",[28,30,110,89,111,112,31],"Uterine Cervical Neoplasms","Triple Negative Breast Neoplasms","Pancreatic Neoplasm",[114,115,116,117,118,119,120,121,122,123,124,125,126,127],"Folate receptor alpha","NSCLC","Ovarian cancer","Cervical cancer","Endometrial cancer","Solid tumor","Lung cancer","Breast cancer","Pancreatic cancer","Colorectal cancer","Anti-drug conjugate","Phase I","Chemotherapy","sofe-m","2026-06-17",{"date":130,"type":38},"2026-06-18",{"date":132,"type":38},"2024-05-20",{"date":134,"type":21},"2027-04",{"name":75,"class":45},23,{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":12,"sex":144,"minAge":18,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":22,"phases":147,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":167},"100642707","phase-3-symbiotic-gyn-18-a-study-to-learn-about-the-study-medicine-called-pf-08634404-in-combination-with-chemotherapy-in-adult-participants-with-advanced-or-recurrent-mmr-proficient-endometrial-cancer-100642707","NCT07578649","Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer","AN INTERVENTIONAL PHASE 3, OPEN LABEL, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH ADVANCED OR RECURRENT MISMATCH REPAIR PROFICIENT ENDOMETRIAL CANCER","Inclusion Criteria:\n\n* Women ≥18 years of age who are confirmed not pregnant at screening.\n* Histologically or cytologically confirmed endometrial cancer that is recurrent or advanced; carcinosarcomas are eligible but pure sarcomas are excluded.\n* Newly diagnosed FIGO Stage III disease with measurable disease per RECIST v1.1, newly diagnosed FIGO Stage IV disease with or without measurable disease, or recurrent disease with or without measurable disease per RECIST v1.1 for which curative treatment with surgery and\u002For radiotherapy is unlikely.\n* For participants with recurrent disease, prior adjuvant systemic anti-cancer therapy is allowed if relapse occurred more than 6 months after the last dose.\n* Must provide tumor tissue for prospective central assessment of MMR and p53 status.\n* Proficient mismatch repair (pMMR) endometrial cancer as determined by central testing.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.\n* Life expectancy of at least 12 weeks.\n* Adequate organ function as defined in the protocol.\n\nExclusion Criteria:\n\n* Prior systemic therapy for first-line advanced or recurrent endometrial cancer.\n* Prior immunotherapy or anti-angiogenic therapy.\n* Deficient mismatch repair (dMMR) endometrial cancer by central testing.\n* Active or untreated central nervous system (CNS) metastases; participants with previously treated and clinically stable brain metastases may be eligible if not requiring steroids and without evidence of progression.\n* Clinically significant risk of bleeding or fistula, including a history of severe bleeding disorders.\n* History of another malignancy within 3 years, except for cancers with negligible risk of recurrence or death.\n* History of allogeneic organ or hematopoietic stem cell transplantation; active autoimmune disease requiring systemic treatment within the past 2 years; or history of immunodeficiency\n* Interstitial lung disease, pneumonitis, or clinically significant pulmonary disease\n* Uncontrolled or significant cardiovascular, metabolic, renal, hepatic, or vascular disease\n* Active or uncontrolled infection.\n* Recent major surgery or severe trauma within protocol-defined washout periods.","FEMALE",{"count":146,"type":21},600,[148],"PHASE3","This study is being conducted to assess whether the study medicine PF 08634404, given in combination with chemotherapy, improves outcomes compared with another medicine called pembrolizumab plus chemotherapy. Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or stop them from growing.\n\nOur bodies have a built-in DNA \"spell-checker,\" called the mismatch repair (MMR) system, that fixes genetic mistakes. In most endometrial cancers, this system works normally, and these cancers are called MMR-proficient (pMMR). However, pMMR tumors are harder for the immune system to recognize and attack. When endometrial cancer has spread beyond the uterus or comes back after previous treatment, it is called advanced or recurrent endometrial cancer. This study is for adults with mismatch repair-pMMR advanced or recurrent endometrial cancer.\n\nParticipants must meet key criteria, including:\n\n* Women who are 18 years or older, and not pregnant at the time of joining the study\n* pMMR endometrial cancer only\n* Measurable Stage III disease, Stage IV disease (with or without measurable disease) per FIGO staging, a system doctors use to describe how far cancer has spread in the body, or recurrent endometrial cancer\n* Has not received chemotherapy except for chemotherapy given after the main surgery and more than 6 months before relapse\n* Be in good enough health to receive study treatment. Approximately 600 adult women will be enrolled. Each participant will be randomly assigned (like a flip of the coin) to one of two treatment groups, with about half in each group. The study is open, meaning both the doctors and participants know what treatment is being given. Participants will receive their assigned treatment through intravenous infusions (medicine is given directly into a vein). The treatment will be given in cycles.\n\nExperimental Group will receive new study medicine called PF-08634404 plus chemotherapy. It will be followed by PF 08634404 alone for up to 2 years (35 cycles).\n\nControl Group will receive an approved medicine called pembrolizumab plus chemotherapy. It will be followed by pembrolizumab alone for up to 2 years (20 cycles).\n\nThe study will include regular visits for:\n\n* Participants will have regular visits to the study site for treatment, health checks, and tests.\n* After stopping treatment, participants will come for a final visit within a month to check their health and review any reactions.\n* Follow-up will continue every 12 weeks by phone or in person or by reviewing health records. This helps check health and any new treatments.\n* Tests will be done every 9 weeks during the first 104 weeks to see how the cancer is responding. After that, tests will be done every 12 weeks.",[30,151],"Endometrial Cancer",[153,30,154,155,156],"Recurrent Endometrial Carcinoma","Advanced Endometrial Carcinoma","Advanced or Recurrent Endometrial Cancer","pMMR","NOT_YET_RECRUITING","2026-06-10",{"date":160,"type":38},"2026-06-12",{"date":162,"type":21},"2026-10-09",{"date":164,"type":21},"2031-01-30",{"name":166,"class":45},"Pfizer",4,{"id":169,"slug":170,"hasResults":12,"nctId":171,"briefTitle":172,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":22,"phases":176,"briefSummary":177,"conditions":178,"keywords":193,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":4},"100643697","phase-2-exploratory-study-on-the-efficacy-and-safety-of-trastuzumab-rezetecan-in-the-treatment-of-her2-expressiong-advanced-solid-tumor-100643697","NCT07631884","Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor","Inclusion Criteria:\n\n1. Male and female participants aged 18 years or older.\n2. Participants with locally advanced, unresectable or metastatic solid tumors who have progressed after at least one prior systemic therapy for advanced\u002Fmetastatic disease, or have no satisfactory alternative treatment options. Eligible tumor types include but are not limited to biliary tract cancer, endometrial cancer, urothelial carcinoma, pancreatic cancer, colorectal cancer, gastric cancer, non-small cell lung cancer, head and neck adenocarcinoma (salivary gland adenocarcinoma, lacrimal gland adenocarcinoma, adenocarcinoma of unknown primary in the neck), cervical cancer, ovarian cancer and adenocarcinoma of unknown primary. Breast cancer is excluded.\n3. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.\n4. Confirmed HER2 expression defined as IHC 1+, 2+ or 3+ (per GC criteria).\n5. Willing and able to provide adequate tumor specimens for central pathological re-testing of HER2 status. For participants previously treated with anti-HER2 therapy, tumor specimens obtained after the last anti-HER2 treatment are optional.\n6. At least one measurable lesion at baseline per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n7. Adequate organ and bone marrow function within 14 days prior to enrollment, meeting the following criteria:\n\n   Hemoglobin ≥ 9 g\u002FdL; Platelet count ≥ 100,000\u002Fmm³; Absolute neutrophil count (ANC) ≥ 1500\u002Fmm³; Serum albumin ≥ 3.0 g\u002FdL; Prothrombin time (PT), activated partial thromboplastin time (aPTT) and International Normalized Ratio (INR) ≤ 1.5 × upper limit of normal (ULN); Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 × ULN; ≤ 5 × ULN for participants with liver metastases; Total bilirubin ≤ 1.5 × ULN for participants without liver metastases; ≤ 3 × ULN for participants with Gilbert's syndrome or liver metastases at baseline; Creatinine clearance ≥ 30 mL\u002Fmin (calculated by the Cockcroft-Gault formula)\n8. Left ventricular ejection fraction (LVEF) ≥ 50% assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days prior to enrollment.\n\nExclusion Criteria:\n\nParticipants meeting any of the following conditions are ineligible for this study:\n\n1. Presence of any severe and\u002For uncontrolled diseases:\n\n   * Poorly controlled blood pressure (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg); poorly controlled diabetes (fasting blood glucose \\[FBG\\] \\> 10 mmol\u002FL).\n   * Grade ≥ 2 myocardial ischemia, myocardial infarction, arrhythmia (QTc interval ≥ 470 ms), or Grade ≥ 2 congestive heart failure (per New York Heart Association \\[NYHA\\] classification).\n   * Active or uncontrolled severe infections (Grade ≥ 2 per NCI CTCAE) requiring systemic antibacterial, antifungal or antiviral therapy, including pulmonary tuberculosis.\n   * History of active tuberculosis.\n   * Uncontrolled ascites, pericardial effusion or pleural effusion requiring repeated drainage.\n2. Active hepatitis: Liver function not meeting the inclusion criteria. Hepatitis B: HBV DNA ≥ 2000 IU\u002FmL or ≥ 10\\^4 copies\u002FmL.Hepatitis C: HCV RNA ≥ 2000 IU\u002FmL or ≥ 10\\^4 copies\u002FmL. Participants with viral load below the above thresholds after nucleoside antiviral therapy are eligible. Chronic hepatitis B virus carriers with HBV DNA \\\u003C 10\\^4 IU\u002FmL must receive concurrent antiviral treatment throughout the study for enrollment.\n3. History of immunodeficiency diseases, including HIV positivity or other acquired\u002Fcongenital immunodeficiency disorders.\n4. History of allogeneic solid organ transplantation or allogeneic hematopoietic stem cell transplantation.\n5. Confirmed meningeal metastasis, spinal cord metastasis or spinal cord compression.\n6. Within 6 months prior to the first study drug administration, presence of esophageal gastric varices, severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, acute gastrointestinal bleeding, extensive intestinal resection (partial colectomy or extensive small bowel resection complicated with chronic diarrhea), Crohn's disease, ulcerative colitis or long-standing chronic diarrhea.\n7. Unhealed or poorly healing wounds, or active ulcers.\n8. Toxicities from prior anti-tumor therapy have not resolved to Grade 0 or 1 per NCI CTCAE version 5.0.\n9. Received major surgery, incisional biopsy or significant traumatic injury within 28 days before study treatment initiation; or with long-standing unhealed wounds or fractures.\n10. History of severe hypersensitivity reactions to monoclonal antibodies; known allergy to the active ingredients or excipients of the study drug.",{"count":175,"type":21},15,[25],"The goal of this clinical trial is to learn if Trastuzumab Rezetecan can treat advanced solid tumors with HER-2 expression in adult participants.\n\nThe main question it aims to answer is: What is the objective response rate of Trastuzumab Rezetecan in adult patients with HER-2 expressed advanced solid tumors? Participants will receive intravenous infusion of Trastuzumab Rezetecan on Day 1 of each 21-day treatment cycle. The dosage is 4.8 mg\u002Fkg per cycle; participants with a body weight of 85 kg or above will receive a fixed dose of 408 mg every 3 weeks.",[179,180,181,182,183,184,185,186,30,187,188,31,189,190,191,192],"Solid Tumors","Neoplasms (Cancer \u002F Tumors)","Advanced Malignant Solid Neoplasm","Locally Advanced Malignant Solid Neoplasm","Unresectable Malignant Solid Neoplasm","Metastatic Malignant Solid Neoplasm","HER2 Expression","Biliary Tract Neoplasms","Urothelial Carcinoma (UC)","Pancreatic Neoplasms","Gastric Neoplasms","Non-Small Cell Lung Carcinoma (NSCLC)","Head and Neck Neoplasms","Cervical Neoplasms",[194,195,196],"HER2 expression","Trastuzumab Rezetecan","Advanced Solid Tumor","2026-06-02",{"date":199,"type":38},"2026-06-08",{"date":201,"type":21},"2026-06-15",{"date":203,"type":21},"2028-12-31",{"name":205,"class":206},"Haihua Yuan","OTHER",{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":12,"sex":144,"minAge":18,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":22,"phases":217,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":5},"100517924","phase-2-a-three-arm-randomized-phase-ii-study-of-dostarlimab-alone-or-with-bevacizumab-versus-nonplatinum-chemotherapy-in-recurrent-gynecological-clear-cell-carcinoma-dove-apgot-ov7-engot-ov80-study-100517924","NCT06023862","A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7\u002F ENGOT-ov80 Study)","A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV07\u002F ENGOT-ov80 Study)","DOVE","Inclusion Criteria:\n\n1. Female patient is at least 18 years of age,\n2. Patient has signed the Informed Consent (ICF) and is able to comply with protocol requirements.\n3. Patient with histologically proven confirmed recurrent or persistent clear cell carcinoma of the ovary, endometrium, cervix, vagina, and vulva\n\n   * Local review by gynecologic pathologist required\n   * ≥50% clear cell histology in case of mixed carcinoma\n   * WT-1 neg (Only in case of ovarian cancer) Note: In the case of including non-ovarian clear cell carcinoma with more than 20 cases, the decision is made through discussion with the SPONSOR.\n4. Patient with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n5. Disease progression within 12 months of completing platinum-based chemotherapy\n6. 1-5 prior lines of therapies\n7. Patient with measurable disease according RECIST 1.1 criteria\n8. Availability of Tumor tissue for translational research . - A formalin-fixed paraffin-embedded (FFPE) tumor block(preferred) or at least 20 slides (unstained, freshly cut, serial sections) must be submitted.\n9. Patients who consent to fresh tumor biopsies\n\n   * Confirmed with at least one lesion with location accessible to safely biopsy per the clinical judgement of the investigator\n   * Note: If mandatory biopsies cannot be performed as per investigator's clinical judgement, discussion and agreement between investigator and Sponsor are required.\n10. Patient has adequate organ function, defined as follows:\n\n    1. Absolute neutrophil count ≥ 1,500 cells\u002FμL\n    2. Platelets ≥ 100,000 cells\u002FμL\n    3. Hemoglobin ≥ 9 g\u002FdL or ≥ 5.6 mmol\u002FL\n    4. Serum creatinine ≤ 1.5× upper limit of normal (ULN) or calculated creatinine clearance ≥ 50 mL\u002Fmin using the Cockcroft-Gault equation for patients with creatinine levels \\> 1.5× institutional ULN\n    5. Total bilirubin ≤ 1.5× ULN (≤ 2.0 x ULN in patients with known Gilbert's syndrome) or direct bilirubin ≤ 1× ULN\n    6. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5× ULN unless liver metastases are present, in which case they must be ≤ 5× ULN\n    7. International normalized ratio or prothrombin time (PT) ≤1.5× ULN and activated partial thromboplastin time ≤1.5× ULN.Participants taking anticoagulants may be included on a stable dose with a therapeutic INR \\\u003C3.5. .\n11. Patient must have a negative serum pregnancy test within 72 hours of the first dose of study medication, unless they are of non-childbearing potential. If a negative result cannot be confirmed by a urine test, a serum pregnancy test is required. Non-childbearing potential is defined as follows:\n\n    1. Patient is ≥ 45 years of age and has not had menses for \\> 1 year.\n    2. A follicle-stimulating hormone value in the postmenopausal range upon screening evaluation if amenorrhoeic for \\\u003C 2 years without a hysterectomy and oophorectomy.\n    3. Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation:\n\n       * Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound, MRI, or CT scan.\n       * Tubal ligation must be confirmed with medical records of the actual procedure.\n       * Information must be captured appropriately within the site's source documents.\n12. Patient of childbearing potential must agree to use a highly effective method of contraception with their partners starting from time of consent through 180 days after the last dose of study treatment. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient (Information must be captured appropriately within the site's source documents).\n\nExclusion Criteria:\n\n1. Patient has had ≥ 6 prior lines of chemotherapy. Surgery of the recurrence is allowed.\n2. Patient has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.\n3. Patient has received prior anticancer therapy (chemotherapy, targeted therapies, hormonal therapy, radiotherapy) within 21 days or \\\u003C 5 times the half-life of the most recent therapy prior to Study Day 1, whichever is shorter.\n\n   Note: Palliative radiation therapy to a small field ≥ 1 week prior to Day 1 of study treatment may be allowed after discussion with the SPONSOR.\n4. Patient with contraindication to chemotherapy or immune checkpoint inhibitor treatments or anti-angiogenic inhibitor\n5. Patients with uncontrolled hypertension (defined as systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥100 mmHg) based on an average of ≥ 3 BP readings on ≥ 2 sessions.\n6. Patients with evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)\n7. Patients with current abdominal\u002Fpelvic fistula\n8. Patient has a concomitant malignancy, or patient has a prior non-gynecological malignancy who has been disease-free for \\\u003C 3 years or who received any active treatment in the last 3 years for that malignancy. Non-melanoma skin cancer is allowed.\n9. Patient has known uncontrolled central nervous system metastases, carcinomatosis meningitis, or both. Note: Patients with previously treated brain metastases may participate provided they are stable (without evidence of disease progression by imaging \\[using the identical imaging modality for each assessment, either MRI or CT scan\\] for at least 4 weeks prior to the first dose of study treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and have not been using steroids for at least 7 days prior to study treatment. Carcinomatous meningitis precludes a patient from study participation regardless of clinical stability.\n10. Patient has a known history of human immunodeficiency virus (HIV; HIV ½ antibodies). Participants with known human immunodeficiency virus(HIV) are allowed if they meet all of the following criteria:\n\n    * Cluster of differentiation 4(CD4) ≥350\u002FμL and viral load \\\u003C50 copies\u002FmL.\n    * No history of acquired immunodeficiency syndrome-defining opportunistic infections within 12 months before enrollment.\n    * No history of HIV-associated malignancy for the past 5 years.\n    * Concurrent antiretroviral therapy as per the most current National Institutes of Health (NIH) Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV started \\>4 weeks before study enrollment.\n11. Patient with presence of hepatitis B surface antigen or a positive hepatitis C antibody test result at screening or within 3 months before first dose of dostarlimab treatment.\n\n    * Participants who are hepatitis B surface antigen positive may be enrolled if their HBV-DNA level is below the institutional lower limit.\n    * Participants with chronic hepatitis B virus (HBV) infection who meet the criteria for anti-HBV therapy may be eligible if the participant is on a suppressive antiviral therapy before initiation of cancer therapy.\n    * Participants with positive hepatitis C antibody due to prior resolved disease can be enrolled only if a confirmatory negative hepatitis C RNA polymerase chain reaction is obtained. Hepatitis C participants may be eligible if they both have completed curative therapy and have a hepatitis C viral load \\\u003C!-- Not Allowed Tag Filtered --\\>\\\u003Cquantifiable limit.\n12. Patient has an active autoimmune disease that required systemic treatment in the past 2 years. Replacement therapy is not considered a form of (eg, thyroid hormone or insulin).\n13. diagnosis immunodeficiency receiving steroid any other immunosuppressive within 7 days prior to first dose study treatment. Patients who have received acute and\\>\u002For low-dose systemic immunosuppressive medications (e.g,, a one-time dose of dexamethasone for nausea or chronic use of ≤ 10 mg\u002Fday of prednisone or dose equivalent corticosteroid) may be enrolled in the study after discussion with and approval by the Sponsor. The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) is allowed.\n14. Patient has not recovered (to Grade ≤ 1) from previous anti-cancer therapy-induced adverse events (AEs).\n\n    Note: Patients with Grade ≤ 2 neuropathy, Grade ≤ 2 alopecia, or Grade ≤ 2 fatigue are an exception to this criterion and may qualify for the study.\n15. Patient has not recovered adequately from AEs or complications from any major surgery prior to starting therapy. Major surgical procedures, other than for diagnosis, within 4 weeks prior to initiation of study treatment\n16. Patient has a known hypersensitivity to bevacizumab or dostarlimab components or excipients.\n17. Patient is currently participating and receiving study treatment or has participated in a study of an investigational agent and received study treatment or used an investigational device within 4 weeks of the first dose of treatment.\n18. Patient is considered a poor medical condition due to a serious, uncontrolled medical disorder, non-malignant systemic disease, or active infection requiring systemic therapy. Specific examples include, but are not limited to, active, non-infectious pneumonitis; uncontrolled ventricular arrhythmia; recent (within 90 days) myocardial infarction; uncontrolled major seizure disorder; unstable spinal cord compression; superior vena cava syndrome; or any psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study (including obtaining informed consent).\n19. Patients with known history of non-infectious pneumonitis that required steroids or has current pneumonitis.\n20. Use of any of the following immunomodulatory agents within 28 days prior to the first dose of study drug:\n\n    * Interferons\n    * Interleukins\n    * Live vaccine Note: Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella\u002Fzoster, yellow fever, rabies, BCG, and typhoid vaccine. mRNA and adenoviral-based COVID-19 vaccines are considered non-live and are not exclusionary. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed as other killed vaccines, if done at least 2 weeks prior the first dose of study drug; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.\n21. Patient who are pregnant or lactating, or plan to become pregnant or lactate during the expected duration of the study, from screening through 180 days after the last dose of study drug.",{"count":216,"type":21},198,[25],"Multicenter, randomized, open-label, phase II clinical study comparing Dostarlimab +\u002F- Bevacizumab with standard chemotherapy in patients with gynecological clear cell carcinoma.\n\n198 subjects will be enrolled in this study and will be assigned to three groups in a 1:1:1 ratio.\n\n1. Group A: Dostarlimab monotherapy\n\n   * First 3 cycles: Dostalimab 500mg every 3 weeks, IV\n   * 4 cycles \\~ up to 24 months: Dostalimab 1000mg every 6 weeks, IV\n2. Group B: Dostarlimab + Bevacizumab combination therapy\n\n   * First 3 cycles: Dostalimab 500mg every 3 weeks, IV\n   * 4 cycles \\~ up to 24 months: Dostalimab 1000mg every 6 weeks, IV\n   * Bevacizumab administered IV at 15 mg\u002Fkg every 3 weeks until disease progression or unacceptable toxicity\n3. Group C: General chemotherapy (one of Pegylated liposomal doxorubicin, Doxorubicin, Paclitaxel, and Gemcitabine)",[28,30,110,220,221,222],"Vulvar Cancer","Vagina Neoplasm","Clear Cell Carcinoma","2026-04-30",{"date":225,"type":38},"2026-05-06",{"date":227,"type":38},"2024-01-22",{"date":229,"type":21},"2029-12-31",{"name":231,"class":206},"Yonsei University",{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":144,"minAge":18,"maxAge":240,"enrollmentInfo":241,"targetDuration":4,"studyType":22,"phases":243,"briefSummary":245,"conditions":246,"keywords":247,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":263},"100492049","uterine-manipulator-versus-no-uterine-manipulator-in-endometrial-cancer-trial-100492049","NCT05687084","Uterine Manipulator Versus no Uterine Manipulator in Endometrial Cancer Trial","Randomized Controlled Trial on the Oncologic Outcomes of Use Versus Not Use of the Uterine Manipulator in the Surgical Treatment of Apparent Uterine-confined Endometrial Carcinoma","MANEC","Inclusion Criteria:\n\n* Diagnosis of Endometrial Cancer of any histology (including carcinosarcoma) and grade\n* Planned surgical treatment including hysterectomy and bilateral salpingo-oophorectomy (ovarian preservation in selected patients is not an exclusion criterion)\n* Age ≥ 18 years\n* No preoperative evidence of extrauterine disease (Clinical stage IIIA, IIIB)\n* No preoperative evidence of suspicious lymph nodes (Clinical stage IIIC)\n* No preoperative evidence of distant metastasis (Clinical stage IV)\n* Approved and signed informed consent\n\nExclusion Criteria:\n\n* Neoadjuvant therapy\n* Synchronous or previous (\\\u003C 5 years) invasive cancer, not including non-melanoma skin cancer\n* Fertility preservation\n* World Health Organization performance score \\> 2\n* Uterine sarcoma\n* Previous pelvic\u002Fabdominal radiotherapy, hormone therapy for cancer (\\\u003C 5 years), chemotherapy (\\\u003C 5 years), pelvic or paraaortic lymphadenectomy, or retroperitoneal surgery\n* Inadequate bone marrow function (white blood cells \\\u003C3·0×109\u002FL, platelets \\\u003C100×109\u002FL)\n* Inadequate liver function (bilirubin \\>1.5×upper normal limit \\[UNL\\], aspartate aminotransferase, and alanine aminotransferase \\>2.5 × UNL)\n* Inadequate kidney function (creatinine clearance \\\u003C 60 mL per min calculated according to Cockcroft-Gault 10 or \\\u003C 50 mL per min Ethylenediaminetetraacetic acid clearance)\n* Intraoperative evidence of stage IV disease","100 Years",{"count":242,"type":21},1030,[244],"NA","Minimally invasive surgery is the recommended approach in endometrial cancer (EC) patients based on the results of two randomized controlled trials, given its advantages without compromised oncologic outcomes. The uterine manipulator is commonly used in benign and malignant pathologies to perform a laparoscopic or robotic hysterectomy. However, although regularly used, the uterine manipulator adoption in EC is a controversial technical aspect due to the raised concerns regarding the possible risk of disruption of the tumor mass, the spread of malignant cells, and seeding of the disease, particularly at the level of the vaginal cuff or spread of tumor cells, with increased risk of recurrence and death due to EC. On that basis, given that hysterectomy without a uterine manipulator is feasible, only a randomized controlled trial comparing oncologic outcomes in EC patients after use versus not use of the uterine manipulator will be able to provide high-quality evidence to answer this critical question and allow or exclude the use of a uterine manipulator during minimally invasive hysterectomy for EC.",[30],[30,248,249,250,251,252,253],"Uterine manipulator","Laparoscopic hysterectomy","Recurrence-free survival","Cause-specific survival","Overall survival","Oncologic outcomes","2026-04-28",{"date":256,"type":38},"2026-05-05",{"date":258,"type":38},"2023-01-16",{"date":260,"type":21},"2031-12-31",{"name":262,"class":206},"Universita di Verona",3,{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":12,"sex":144,"minAge":18,"maxAge":271,"enrollmentInfo":272,"targetDuration":4,"studyType":22,"phases":274,"briefSummary":275,"conditions":276,"keywords":278,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":299},"100557009","phase-2-cadonilimab-with-chemoradiation-for-recurrent-and-oligometastatic-endometrial-carcinoma-100557009","NCT06532539","Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma","A Phase II, Single-arm, Multicenter Clinical Trial of Definitive Treatment With Cadonilimab, Paclitaxel, Cisplatin and Radiation for the Treatment of Locally Recurrent and Oligometastatic Endometrial Carcinoma","Inclusion Criteria:\n\n1. A written informed consent form must be signed before the implementation of any trial-related procedures.\n2. Female, aged 18 years or older and 80 years or younger.\n3. ECOG PS 0-1.\n4. Newly diagnosed with histologically or cytologically confirmed primary endometrioid adenocarcinoma, serous carcinoma, clear cell adenocarcinoma, undifferentiated carcinoma, mixed cell adenocarcinoma, mesonephric adenocarcinoma, mucinous carcinoma, intestinal-type mesonephric-like adenocarcinoma, and carcinosarcoma, meeting the clinical diagnostic criteria for endometrial cancer.\n5. Patients with locally recurrent or oligometastatic endometrial cancer after initial treatment. The number of recurrent and metastatic lesions is ≤5. Screening criteria for oligometastasis: lymph node metastases in the same region count as one metastatic lesion; liver metastases are limited to one; lung metastases are limited to three.\n6. At least one site suitable for radiotherapy (including the primary lesion), measurable, and meeting the RECIST v1.1 criteria for evaluable lesions.\n7. Tumor samples available for biomarker assessment.\n8. Expected survival time ≥6 months.\n9. Normal major organ function (within 7 days before enrollment), meeting the following criteria:\n\n(1) Hematology standards (without blood transfusion or hematopoietic growth factor treatment within 14 days before enrollment):\n\n1. Hemoglobin (HB) ≥80 g\u002FL;\n2. Absolute neutrophil count (ANC) ≥1.5×10\\^9\u002FL;\n3. Platelet count (PLT) ≥50×10\\^9\u002FL; (2) No functional or organic diseases, meeting the following criteria:\n\na) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN, total serum bilirubin ≤1.5×ULN, alkaline phosphatase (ALP) ≤3×ULN, serum albumin ≥30 g\u002FL; b) Serum creatinine (Cr) ≤1.5×ULN; if serum creatinine is \\>1.5×ULN, creatinine clearance (CrCl) ≥50 mL\u002Fmin (calculated using the Cockcroft-Gault formula); c) Prothrombin time (PT) prolongation ≤6 seconds, activated partial thromboplastin time (APTT) ≤1.5×ULN; d) Thyroid-stimulating hormone (TSH) ≤ULN (if abnormal, FT3 and FT4 levels should be considered; if FT3 and FT4 levels are normal, enrollment is allowed); f) Left ventricular ejection fraction (LVEF) \\>50%. 11. Before starting the first treatment, all reversible toxic reactions from previous anti-tumor treatments must have resolved to ≤ grade 1 (based on CTCAE v5.0), excluding any grade of alopecia and pigmentation, ≤ grade 2 peripheral sensory neuropathy, and other abnormalities considered by the investigator and\u002For sponsor to pose a benefit-risk balance favoring the subject receiving the study treatment.\n\n12\\. Non-surgically sterilized or childbearing potential female patients must use medically recognized contraception (e.g., intrauterine device, contraceptive pill, or condom) during the study treatment period and for 3 months after the end of the study treatment. Non-surgically sterilized childbearing potential female patients must have a negative serum or urine HCG test within 7 days before enrollment and must not be breastfeeding.\n\nExclusion Criteria:\n\n1. Subjects with any active autoimmune disease or history of autoimmune disease (e.g., but not limited to: autoimmune hepatitis, interstitial lung disease, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism; subjects with vitiligo or childhood asthma that has completely resolved and does not require any intervention in adulthood may be included; subjects with asthma requiring medical intervention with bronchodilators are not eligible).\n2. Subjects currently using immunosuppressive agents or systemic, or absorbable local corticosteroid therapy to achieve immunosuppressive purposes (dose \\>10 mg\u002Fday prednisone or equivalent) and continuing use within 2 weeks prior to enrollment.\n3. Known history of grade 3 or 4 immune-related adverse events associated with previous anti-tumor immunotherapy.\n4. Poorly controlled cardiac clinical symptoms or diseases, such as: (1) NYHA class II or higher heart failure; (2) unstable angina; (3) myocardial infarction within the past six months; (4) clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention; (5) QTc \\>450 ms (males); QTc \\>470 ms (females).\n5. Coagulation dysfunction (INR \\>1.5 or PT \\>16 s), bleeding tendency, or receiving thrombolytic or anticoagulant therapy.\n6. Subjects who have received radiotherapy, chemotherapy, hormone therapy, surgery, or molecular targeted therapy within 4 weeks (or 5 drug half-lives, whichever is longer) prior to the first dose of the study drug; subjects with adverse events from previous treatments (excluding alopecia) that have not recovered to ≤CTCAE grade 1.\n7. Subjects with clinically uncontrolled third-space effusion requiring puncture drainage or other local treatment prior to the first dose of the investigational drug.\n8. Subjects with significant hemoptysis within 2 months before randomization, or hemoptysis of at least half a teaspoon (2.5 ml) per day.\n9. Known hereditary or acquired bleeding and thrombotic tendencies (e.g., hemophilia, coagulation dysfunction, thrombocytopenia, hypersplenism).\n10. Subjects with active infection or unexplained fever \\>38.5°C during the screening period or prior to the first dose.\n11. Subjects with a history of or current evidence of lung fibrosis, interstitial lung disease, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis, or severely impaired lung function.\n12. Subjects with congenital or acquired immune deficiencies (e.g., HIV infection) or active hepatitis (hepatitis B reference: HBV DNA exceeding the upper limit of normal; hepatitis C reference: HCV viral load or RNA exceeding the upper limit of normal).\n13. Subjects who have used other investigational drugs or similar therapeutic agents within 4 weeks prior to the first dose or who have received radiotherapy or other local treatments within 2 weeks prior to the first dose and have not recovered from the adverse effects of such treatments.\n14. Subjects with a history of or concurrent other malignancies (excluding cured basal cell carcinoma of the skin and cervical carcinoma in situ).\n15. Subjects who may receive other systemic anti-tumor therapies during the study period.\n16. Subjects who have received or are expected to receive live vaccines within 4 weeks prior to the first dose or during the study period.\n17. Subjects with other factors that may lead to forced termination of the study as judged by the investigator, such as severe diseases (including mental disorders) requiring combined treatment, severe laboratory abnormalities, and family or social factors that may affect the safety of the subject or the collection of data and samples.","80 Years",{"count":273,"type":21},30,[25],"The goal of this clinical trial is to evaluate the efficacy and safety of cadonilimab in combination with paclitaxel, cisplatin, and radiation therapy for the treatment of locally recurrent and oligometastatic endometrial carcinoma. The main questions it aims to answer are:\n\n1. Does the combination therapy improve the overall response rate (ORR), progression-free survival (PFS), disease control rate (DCR), overall survival (OS), and safety in participants?\n2. What are the predictive biomarkers of treatment efficacy, and how can this information better guide the use of immune-oncology drugs in combination therapy?\n\nParticipants will:\n\n* Receive cadonilimab, paclitaxel, cisplatin, and radiation therapy according to a specified protocol.\n* Visit the clinic for regular checkups and tests throughout the treatment period.\n* Be monitored for and have records kept of ORR, PFS, DCR, OS, and safety.\n* Provide hematologic and tissue samples to explore biomarkers.\n\nThis study will help determine if this combination therapy can become a new standard of care for patients with locally recurrent and oligometastatic endometrial carcinoma, as well as identify biomarkers to better guide treatment strategies.",[30,277,62],"Neoplasm Recurrence, Local",[279,280,281,282,283,284,285,286,287,288,289],"Immunotherapy","Cadonilimab","Paclitaxel","Cisplatin","Radiation Therapy","Combined Modality Therapy","Clinical Trials, Phase II as Topic","Progression-Free Survival","Biomarkers, Tumor","Treatment Outcome","Safety","2026-04-21",{"date":292,"type":38},"2026-04-24",{"date":294,"type":38},"2024-06-13",{"date":296,"type":21},"2026-09",{"name":298,"class":206},"Shandong Cancer Hospital and Institute",1,{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":4,"eligibilityCriteria":306,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":22,"phases":309,"briefSummary":310,"conditions":311,"keywords":333,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":348},"100561192","phase-1-a-study-with-nkt3964-for-adults-with-advancedmetastatic-solid-tumors-100561192","NCT06586957","A Study With NKT3964 for Adults With Advanced\u002FMetastatic Solid Tumors","A Phase 1, First-in-human, Open-label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral CDK2 Degrader NKT3964 in Adults With Advanced\u002FMetastatic Solid Tumors","Inclusion Criteria:\n\n\\- Must have a pathologically confirmed advanced and unresectable or metastatic solid tumor listed below with documented disease progression on last standard treatment. Part 1 only: subjects must be refractory to, or intolerant of existing therapy(ies) known to provide clinical benefit for their condition.\n\nDose Escalation:\n\n1. Ovarian cancer\n2. Endometrial cancer (only endometrioid subtype will require CCNE1 amplification)\n3. Gastric, gastroesophageal junction (GEJ) or esophageal adenocarcinoma with CCNE1 amplification\n4. Small cell lung cancer (SCLC)\n5. Triple-negative breast cancer (TNBC; HER2, estrogen receptor and progesterone receptor negative)\n6. HR+ (includes estrogen-receptor or progesterone-receptor) and HER2- breast cancer (must have progressed following treatment with a CDK4\u002F6 inhibitor, and is not suitable for endocrine therapy \\[ET\\])\n7. Other solid tumors with CCNE1 amplification\n\nDose Expansion:\n\nPart 2A: HR+ and HER2- breast cancer that is locally advanced and unresectable (Stage III) or metastatic (Stage IV); previously treated with ≥1 line of standard of care (SOC) including CDK4\u002F6 inhibitor plus ET and not suitable for further ET. Subjects must have progressed after receiving therapy for ≥3 months in the metastatic setting or for ≥6 months in the adjuvant setting. Subjects must have received ≤2 lines of systemic cytotoxic therapy (chemotherapy or cytotoxic antibody drug conjugate \\[ADC\\]) in the metastatic setting..\n\nPart 2B: Advanced platinum-based-chemotherapy resistant or refractory epithelial ovarian\u002Ffallopian\u002Fprimary peritoneal carcinoma or clear cell ovarian cancer (defined as recurrence ≤6 months after completing platinum-based regimen) with progression on at least one platinum containing therapy and previously treated with ≤4 prior lines of systemic therapy administered for advanced\u002Fmetastatic disease and with CCNE1 amplification.\n\nPart 2C: Advanced unresectable or metastatic gastric, GEJ or esophageal adenocarcinoma with progression on at least one systemic therapy and previously treated with ≤3 prior lines of systemic therapy administered for advanced\u002Fmetastatic disease, with CCNE1 amplification as determined by NGS by local liquid or tissue test.\n\nPart 2D: Advanced endometrial adenocarcinoma or uterine papillary serous carcinoma previously treated with ≤4 prior lines of systemic therapy administered for advanced\u002Fmetastatic disease with CCNE1 amplification.\n\nPart 2E: Advanced\u002Frecurrent uterine carcinosarcoma previously treated with 1 prior platinum-based chemotherapy regimen and ≤3 prior lines of systemic therapy. Prior bevacizumab or PARP inhibitors are allowed and must be at least 3 weeks prior to the start of study drug.\n\n* Have adequate organ function\n* Subjects with female reproductive organs must be surgically sterile, post-menopausal, or must be willing to use highly effective method(s) of contraception\n* Ability to swallow oral medications.\n* Consent to provide archived tumor tissues and paired tumor biopsy at pretreatment\n\nExclusion Criteria:\n\n* Locally advanced solid tumor that is a candidate for curative treatment through radical surgery and\u002For radiotherapy, or chemotherapy.\n* History of another malignancy with exceptions\n* History of lymphohistiocytic or lymphoid hyperplasia; hemophagocytic lymphohistiocytosis.\n* Failed to recover from effects of prior anticancer treatment therapy to baseline or Grade ≤ 1 severity (per CTCAE)\n* Clinically significant cardiovascular event within 6 months prior to start of NKT3964 treatment\n* Known active CNS metastases and\u002For carcinomatous meningitis\n* Active interstitial lung disease currently requiring treatment\n* History of uveitis, retinopathy or other clinically significant retinal disease\n* Active or chronic corneal disorders, other active ocular conditions requiring ongoing therapy, or any clinically significant corneal disease\n* Active wound healing from major surgery within 1 month or minor surgery within 10 days before the first dose of NKT3964.\n* Known human immunodeficiency virus (HIV), active hepatitis B or C infection\n* Prior investigative treatment with a selective or nonselective CDK2 inhibitor or degrader\n* Childs-Pugh class B or C cirrhosis or any other clinically significant liver disorder\n* Palliative radiation therapy within 14 days or other radiation therapy within 4 weeks prior to C1D1",{"count":308,"type":21},150,[24],"The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the preliminary anti-tumor activity of NKT3964 at the RDE based on objective response rate (ORR) and determine the preliminary recommended Phase 2 dose (RP2D).",[312,196,313,314,315,28,316,317,30,318,319,91,320,154,321,322,323,324,325,326,90,111,327,328,329,330,331,332],"Solid Tumor","Solid Tumor, Adult","Metastatic Tumor","Ovarian Cancer","Ovarian Carcinoma","Metastatic Ovarian Carcinoma","Endometrial Diseases","Metastatic Endometrial Cancer","Metastatic Endometrial Carcinoma","Advanced Ovarian Carcinoma","Gastric Cancer","Advanced Gastric Carcinoma","Metastatic Gastric Cancer","Metastatic Gastric Carcinoma","Small Cell Lung Cancer","Platinum-resistant Ovarian Cancer","Platinum-refractory Ovarian Carcinoma","CCNE1 Amplification","Hormone Receptor Negative Breast Carcinoma","Human Epidermal Growth Factor 2 Negative Carcinoma of Breast","Progesterone-receptor-positive Breast Cancer",[334,335,336,337,338,339],"CDK 2 Inhibitor","CDK 4 Inhibitor","CDK 6 Inhibitor","CDK2 Degrader","Protein Degrader","PROTAC","2026-04-16",{"date":290,"type":38},{"date":343,"type":38},"2024-09-19",{"date":345,"type":21},"2029-05",{"name":347,"class":45},"NiKang Therapeutics, Inc.",19,{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":355,"eligibilityCriteria":356,"healthyVolunteers":12,"sex":144,"minAge":18,"maxAge":4,"enrollmentInfo":357,"targetDuration":359,"studyType":360,"phases":4,"briefSummary":361,"conditions":362,"keywords":367,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":299},"100449245","registry-platform-ovarian-and-endometrial-cancer-100449245","NCT05129969","Registry Platform Ovarian and Endometrial Cancer","SMARAGD - Clinical Research Platform on Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancer Treatment and Outcomes","SMARAGD","Inclusion Criteria:\n\n* Confirmed high grade OC (advanced or metastatic epithelial ovarian, fallopian tube and primary peritoneal cancer):\n\n  * patients with FIGO stage IIb-IV OC who are starting systemic treatment or\n  * patients with recurrent\u002Frelapsed disease, who received any previous systemic anti-tumor treatment and who are now starting systemic treatment for recurrent\u002Frelapsed disease.\n* Locally advanced and inoperable or metastatic EC (FIGO stage III-IV) who are starting systemic first-line therapy.\n* Signed and dated informed consent (IC):\n\n  * Patients participating in PRO module: IC before first therapy cycle\n  * Patients not participating in PRO module: IC no later than six weeks after start of first therapy cycle\n\nExclusion Criteria:\n\n* newly diagnosed early-stage OC (FIGO stage I-IIa)\n* Low grade mOC OR\n* Early-stage EC (FIGO stage I-II)",{"count":358,"type":21},1975,"3 Years","OBSERVATIONAL","The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with advanced or metastatic ovarian cancer (OC) or advanced or metastatic endometrial cancer (EC) in Germany.",[315,151,363,30,364,365,366],"Ovary Neoplasm","Carcinoma, Ovarian","Carcinoma","Neoplasm, Ovarian",[368,369,370,371,372,373],"Registry","Health service research","Epidemiology","Germany","Palliative treatment","Palliative care","2026-01-26",{"date":376,"type":38},"2026-01-28",{"date":378,"type":38},"2021-11-25",{"date":380,"type":21},"2030-12",{"name":382,"class":45},"iOMEDICO AG",{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":12,"sex":144,"minAge":18,"maxAge":4,"enrollmentInfo":391,"targetDuration":4,"studyType":360,"phases":4,"briefSummary":393,"conditions":394,"keywords":4,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":4},"100615907","cervical-cytology-dna-methylation-for-endometrial-lesion-screening-and-follow-up-100615907","NCT07298707","Cervical Cytology DNA Methylation for Endometrial Lesion Screening and Follow-up","A Multicenter Study on Cervical Cytology DNA Methylation for Screening and Follow-up of Endometrial Lesions","EndoMethy-V","Inclusion Criteria:\n\n1. Participants must be 18 years of age or older.\n2. Participants must possess medium-to-high risk factors for endometrial cancer as defined by Chinese consensus guidelines and are scheduled for hysteroscopic evaluation; OR are currently undergoing conservative treatment (e.g., progesterone therapy or endometrial ablation) for endometrial lesions, and have not received chemotherapy.\n3. Participants must be capable and willing to provide written informed consent.\n4. Participants must be willing to undergo at least one follow-up assessment within 1 year.\n5. Participants must have an intact cervix (a history of LEEP or conization is acceptable).\n\nExclusion Criteria:\n\n1. Current treatment for any gynecologic malignancy other than endometrial cancer.\n2. Current or untreated cervical, vaginal, or vulvar intraepithelial neoplasia or carcinoma.\n3. History of total or subtotal hysterectomy, trachelectomy, radical trachelectomy, or pelvic radiotherapy.\n4. Active lower genital tract bleeding.\n5. Immunosuppressed state (e.g., HIV infection, status post organ transplantation).\n6. Failure to undergo the planned hysteroscopic evaluation and follow-up within 1 year after the initial assessment.\n7. Failed hysteroscopic procedure.\n8. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for inclusion in the study.",{"count":392,"type":21},3500,"The goal of this observational study is to evaluate the accuracy of a novel molecular test for screening and monitoring endometrial lesions in women at medium-to-high risk for endometrial cancer.\n\nThe main questions it aims to answer are:\n\n* What is the sensitivity and specificity of the CISENDO test (a DNA methylation test on cervical cytology samples) for detecting histologically confirmed endometrial intraepithelial neoplasia (EIN) or invasive endometrial cancer?\n* How do DNA methylation levels change during the follow-up of endometrial lesions? Researchers will compare the results of the CISENDO test to the results from the standard diagnostic procedure (hysteroscopy with histology) to see if the molecular test can reliably identify high-risk lesions and track disease progression.\n\nParticipants will:\n\n* Provide a residual liquid-based cervical cytology sample for the CISENDO test.\n* Undergo a standard diagnostic hysteroscopy examination (with or without biopsy) for comparison.\n* Some participants will return for follow-up visits at 6 and 12 months for repeat methylation testing and\u002For hysteroscopy to monitor their condition.",[30,395,396,397,398],"DNA Methylation","Cervical Smears","Early Detection of Cancer","Endometrial Hyperplasia","2025-12-09",{"date":401,"type":38},"2025-12-23",{"date":403,"type":21},"2026-01-10",{"date":405,"type":21},"2026-12-31",{"name":407,"class":206},"Peking Union Medical College Hospital",{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":414,"eligibilityCriteria":415,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":416,"targetDuration":4,"studyType":22,"phases":417,"briefSummary":418,"conditions":419,"keywords":428,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":5},"100498426","phase-2-determine-trial-treatment-arm-02-atezolizumab-in-adult-paediatric-and-teenageyoung-adult-patients-with-cancers-with-high-tumour-mutational-burden-tmb-or-microsatellite-instability-high-msi-high-or-proven-constitutional-mismatch-repair-deficiency-cmmrd-disposition-100498426","NCT05770102","DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage\u002FYoung Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition","DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage\u002FYoung Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage\u002FYoung Adult Patients With Cancers With High TMB or MSI-high or Proven CMMRD Disposition.","DETERMINE","THE PATIENT MUST FULFIL THE ELIGIBILITY CRITERIA WITHIN THE DETERMINE MASTER PROTOCOL (NCT05722886) AND WITHIN THE TREATMENT ARM 02 (ATEZOLIZUMAB) OUTLINED BELOW\\*\n\n\\*When atezolizumab-specific inclusion\u002Fexclusion criteria or precautions below differ from those specified in the Master Protocol, the atezolizumab-specific criteria will take precedence.\n\nInclusion Criteria:\n\nA. Confirmed diagnosis of a malignancy that is high TMB (defined as ≥10 mut\u002FMb), MSI-high or of proven (previously diagnosed) CMMRD disposition using an analytically validated next-generation sequencing method. Patient cases with TMB between 10-15 mut\u002FMb may be discussed in an MTB meeting. TMB ≥19 mut\u002FMb will be fast-tracked for an MTB recommendation, unless there are any patient-specific individualities (such as multiple gene amplifications) that require MTB discussion.\n\nB. Women of childbearing potential are eligible provide they meet the following criteria:\n\n* Have a negative serum or urine pregnancy test before enrolment and;\n* Agree to use one form of effective birth control method such as:\n\nI. combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (\\[oral, intravaginal or transdermal\\]);\n\nII. progestogen-only hormonal contraception associated with or without inhibition of ovulation (oral, injectable or implantable);\n\nIII. intrauterine device (IUD),\n\nIV. intrauterine hormone-releasing system (IUS),\n\nV. bilateral tubal occlusion,\n\nVI. vasectomised partner,\n\nVII. sexual abstinence,\n\nVIII. male or female condom with or without spermicide;\n\nIX. cap, diaphragm or sponge with spermicide.\n\nEffective from the first administration of atezolizumab, throughout the trial and for five months after the last administration of atezolizumab.\n\nC. Male patients with partners who are women of childbearing potential are eligible provided that they agree to the following, from the first administration of atezolizumab, throughout the trial until the last administration of atezolizumab:\n\n* Agree to take measures not to father children by using a barrier method of contraception (condom plus spermicide) or sexual abstinence.\n* Non-vasectomised male patients with partners who are women of childbearing potential must also be willing to ensure that their partner uses an effective method of contraception.\n* Male patients with pregnant or lactating partners must be advised to use barrier method contraception (e.g. condom) to prevent drug exposure of the foetus or neonate.\n\nAll male patients must refrain from donating sperm for the same period.\n\nD. Patients must be able and willing to undergo a fresh tissue biopsy at baseline and blood samples for translational research. Note that for patients with haematological malignancies or neuroblastomas, blood, bone marrow aspiration and\u002For trephine or lymph node biopsy samples may be taken.\n\nE. ADULT PATIENTS (≥18 years): Adequate organ function as per haematological and biochemical indices within the ranges defined in the protocol. These measurements should be performed to confirm the patient's eligibility.\n\nF. PAEDIATRIC PATIENTS (\\\u003C18 years): Adequate organ function as per haematological and biochemical indices within the ranges defined in the protocol. These measurements should be performed to confirm the patient's eligibility.\n\nG. Patients must have stable thyroid function tests. Patients on stable doses of thyroxine replacement are permitted.\n\nExclusion Criteria:\n\nA. Diagnosis of urothelial cancer, non-small cell lung cancer, extensive-stage small cell lung cancer, hepatocellular carcinoma or triple negative breast cancer.\n\nB. Patients with rapidly progressing or symptomatically deteriorating brain metastases and\u002For leptomeningeal disease. Patients with previously treated brain metastases are eligible, provided the patient has not experienced a seizure or had a clinically significant change in neurological status within 14 days (for adult patients) or 7 days (for paediatric patients) prior to the start of IMP administration. Such patients must be non-dependent on steroids or on a stable or reducing dose of steroid treatment for at least 14 days (or 7 days for paediatric patients) prior to the start of IMP administration. Primary brain or central nervous system (CNS) malignancies are allowed providing the patient is clinically stable (if requiring corticosteroids must be at stable or decreasing doses for at least 14 days for adults and 7 days for paediatric patients prior to the start of IMP administration). Patients who have received brain irradiation must have completed whole-brain radiotherapy and\u002For stereotactic radiosurgery at least 14 days prior to the start of IMP administration.\n\n• Paediatric patients with either primary brain tumours or extracranial solid tumours with intracranial metastases with one or more intracranial lesions should only be considered for inclusion if largest intracranial lesion is ≤6 cm in longest axis. Consideration should also be given to the intracranial location of the tumour and potential risk should swelling occur. This is because of the class risk of immune checkpoint inhibitors such as atezolizumab causing immune-mediated inflammatory response and 'tumour flare' which may result in acute neurological deterioration.\n\nC. Female patients who are pregnant, breastfeeding or planning to become pregnant during the trial or within five months following their last dose of atezolizumab.\n\nD. History or clinical evidence of current inflammatory lung disease:\n\n* History of idiopathic pulmonary fibrosis, organising pneumonia (e.g. bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis.\n* Evidence of active pneumonitis on screening chest computed tomography (CT) scan.\n\nE. Active autoimmune disease that requires the use of systemic immunomodulatory therapy (i.e. with disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy for hypothyroidism and adrenal or pituitary insufficiency is acceptable.\n\nF. Ongoing lung pathologies which, in the opinion of the Investigator present a compromise to safety (e.g. active tuberculosis).\n\nG. Systemic immunomodulatory agents within 14 days prior to trial entry (immunostimulatory agents within four weeks). Exceptions to this are:\n\n* Patients who received acute, low dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g. 48 hours of corticosteroids for a contrast allergy) are eligible for the trial.\n* Patients who received corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma equivalent to ≤10 mg prednisolone a day or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the trial.\n* Patients with primary CNS disease can be receiving concurrent treatment with corticosteroids. Patients must be receiving a stable or decreasing dose for ≥14 days for adults and ≥7 days for paediatric patients prior to the screening magnetic resonance imaging (MRI) scan and at the time of drug initiation.\n* Patients who receive physiological doses of steroid replacement (e.g. hydrocortisone) are permitted.\n\nH. Known to be serologically positive (as detected by polymerase chain reaction) for hepatitis B, hepatitis C or human immunodeficiency virus (HIV).\n\nI. History of severe allergic anaphylactic reactions to chimeric, human or humanised antibodies, or fusion proteins including other immune checkpoint inhibitors.\n\nJ. Known hypersensitivity to Chinese hamster ovary cell products.\n\nK. Known hypersensitivity to atezolizumab or any of the excipients.\n\nL. Patients who were administered a live, attenuated vaccine within 28 days prior to enrolment, or anticipation of need for such a vaccine during atezolizumab treatment or within six months after the final dose of atezolizumab.\n\nM. Patients with clinically significant pre-existing cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or NYHA class III or IV congestive heart failure.\n\nPatients with a cerebrovascular event (including stroke or transient ischaemic attacks \\[TIA\\]) or cardiovascular event (including acute myocardial infarction \\[MI\\]) within three months before the first dose of atezolizumab.\n\n• Patients with primary CNS tumours may be considered unless intra-tumoural bleeding has occurred within 2 weeks of the first dose of atezolizumab, and patients with punctate CNS haemorrhages \\\u003C3 mm may be considered.\n\nPatients with a prior history of pericardial disorders, including pericarditis, pericardial effusion and cardiac tamponade.\n\nN. Prior allogeneic stem cell or solid organ transplantation on immunosuppression.\n\nO. Prior treatment with the same class of drug unless genetic profile demonstrates a mechanism of resistance known to be potentially sensitive to atezolizumab.\n\nP. Uncontrolled diabetes.\n\nQ. Any clinically significant concomitant disease or condition (or its treatment) that could interfere with the conduct of the trial or absorption of oral medications or that would, in the opinion of the Investigator, pose an unacceptable risk to the patient in this trial.\n\nR. Severe infection within four weeks prior to the first IMP administration or the administration of antibiotics within two weeks prior to the first IMP administration, with the exemption of patients requiring prophylaxis.",{"count":273,"type":21},[25,148],"This clinical trial is looking at a drug called atezolizumab. Atezolizumab is approved as standard of care treatment for adult patients with urothelial cancer, non-small cell lung cancer, extensive-stage small cell lung cancer, hepatocellular carcinoma and triple negative breast cancer. This means it has gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK.\n\nAtezolizumab works in patients with these types of cancers which have certain changes in the cancer cells called high tumour mutational burden (TMB) or high microsatellite instability (MSI) or proven (previously diagnosed) constitutional mismatch repair deficiency (CMMRD).\n\nInvestigators now wish to find out if it will be useful in treating patients with other cancer types which are also TMB\u002FMSH-high or show CMMRD. If the results are positive, the study team will work with the NHS and the Cancer Drugs Fund to see if these drugs can be routinely accessed for patients in the future.\n\nThis trial is part of a trial programme called DETERMINE. The programme will also look at other anti-cancer drugs in the same way, through matching the drug to rare cancer types or ones with specific mutations.",[420,421,422,423,424,425,31,30,426,427],"Malignancy","Malignant Neoplasm","Lymphoproliferative Disorders","Neoplasms by Histologic Type","Neoplasms by Site","Cancer","Melanoma","Solid Tumours",[429,430,431,425,432,420,433,434,423,424,435,436,437,438,439],"Adult","Antineoplastic Agents","Atezolizumab","Child","Malignant Neoplasms","Molecular Targeted Therapy","Paediatric","Precision Medicine","Rare","Tumour-agnostic","Young adult","2025-11-19",{"date":442,"type":38},"2025-11-24",{"date":444,"type":38},"2023-10-25",{"date":446,"type":21},"2029-10",{"name":448,"class":206},"Cancer Research UK",{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":4,"eligibilityCriteria":455,"healthyVolunteers":12,"sex":144,"minAge":18,"maxAge":456,"enrollmentInfo":457,"targetDuration":4,"studyType":22,"phases":459,"briefSummary":460,"conditions":461,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":473},"100545224","phase-2-gnrha--letrozole-in-obese-progestin-insensitive-endometrial-cancer-patients-100545224","NCT06379113","GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients","Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole in Obese Progestin-insensitive Early-stage Endometrial Cancer Patients With Conservative Treatment","Inclusion Criteria:\n\n* Have a confirmed initial pathological diagnosis based upon hysteroscopy: histologically prove well-differentiated EEC G1 without myometrial invasion\n* BMI≥30kg\u002Fm2\n* No signs of suspicious extrauterine involvement on enhanced magnetic resonance imaging (MRI) or enhanced computed tomography (CT) or ultrasound\n* Using progestin, any of the following therapy, as first-line treatment:\n\n  1. Megestrol acetate ≥ 160 mg qd using, combined with Levonorgestrel Lntrauterine System (LNG-IUS) inserted or not\n  2. Medroxyprogesterone acetate ≥ 250 mg qd using, combined with LNG-IUS inserted or not\n  3. LNG-IUS inserted\n* Progestin-insensitive:\n\n  1. remained with stable disease after 7 months of progestin use\n  2. did not achieve CR after 10 months of progestin use\n* Have a desire for remaining reproductive function or uterus\n* Good compliance with adjunctive treatment and follow-up\n\nExclusion Criteria:\n\n* Combined with severe medical disease or severely impaired liver and kidney function\n* Pathologically confirmed as endometrial cancer with suspicious myometrial invasion or extrauterine metastasis\n* Patients with other types of endometrial cancer or other malignant tumors of the reproductive system\n* Patients with breast cancer or other hormone- dependent tumors or diseases that cannot be used with GnRHa or Letrozole\n* Strong request for uterine removal or other conservative treatment\n* Known or suspected pregnancy\n* Acute severe disease such as stroke or heart infarction or a history of thrombosis disease\n* Smoker(\\>15 cigarettes a day)","45 Years",{"count":458,"type":21},29,[25,148],"To investigate the efficacy of GnRHa plus letrozole in obese progestin-insensitive EEC patients.",[30,462,463,464],"Atypical Endometrial Hyperplasia","Progesterone Resistance","Obesity",{"date":466,"type":38},"2025-08-11",{"date":468,"type":38},"2022-07-13",{"date":470,"type":21},"2027-03-30",{"name":472,"class":206},"Xiaojun Chen",2,{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":12,"sex":144,"minAge":18,"maxAge":456,"enrollmentInfo":481,"targetDuration":4,"studyType":22,"phases":483,"briefSummary":484,"conditions":485,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":486,"startDateStruct":487,"completionDateStruct":488,"leadSponsor":489,"locationsCount":473},"100463610","phase-2-gnrha--letrozole-in-non-obese-progestin-insensitive-endometrial-cancer-and-atypical-hyperplasia-patients-100463610","NCT05316935","GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients","Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole in Non-obese Progestin-insensitive Early-stage Endometrial Cancer and Atypical Hyperplasia Patients With Conservative Treatment","Inclusion Criteria:\n\n* Have a confirmed initial pathological diagnosis based upon hysteroscopy: histologically prove EAH or well-differentiated EEC G1 without myometrial invasion\n* BMI\\\u003C30kg\u002Fm2\n* No signs of suspicious extrauterine involvement on enhanced magnetic resonance imaging (MRI) or enhanced computed tomography (CT) or ultrasound\n* Using progestin, any of the following therapy, as first-line treatment:\n\n  1. Megestrol acetate ≥ 160 mg qd using, combined with Levonorgestrel Lntrauterine System (LNG-IUS) inserted or not\n  2. Medroxyprogesterone acetate ≥ 250 mg qd using, combined with LNG-IUS inserted or not\n  3. LNG-IUS inserted\n* Progestin-insensitive:\n\n  1. remained with stable disease after 7 months of progestin use\n  2. did not achieve CR after 10 months of progestin use\n* Have a desire for remaining reproductive function or uterus\n* Good compliance with adjunctive treatment and follow-up\n\nExclusion Criteria:\n\n* Combined with severe medical disease or severely impaired liver and kidney function\n* Pathologically confirmed as endometrial cancer with suspicious myometrial invasion or extrauterine metastasis\n* Patients with other types of endometrial cancer or other malignant tumors of the reproductive system\n* Patients with breast cancer or other hormone- dependent tumors or diseases that cannot be used with Diane-35, GnRHa, Letrozole or MET\n* Strong request for uterine removal or other conservative treatment\n* Known or suspected pregnancy\n* Acute severe disease such as stroke or heart infarction or a history of thrombosis disease\n* Smoker(\\>15 cigarettes a day)",{"count":482,"type":21},80,[25,148],"To investigate the efficacy of GnRHa plus letrozole vs Diane-35 plus metformin in non-obese progestin-insensitive early-stage endometrial cancer (EEC) and atypical hyperplasia(EAH) patients asking for conservative treatment.",[30,462,463],{"date":466,"type":38},{"date":468,"type":38},{"date":470,"type":21},{"name":472,"class":206},{"id":491,"slug":492,"hasResults":12,"nctId":493,"briefTitle":494,"officialTitle":494,"acronym":4,"eligibilityCriteria":495,"healthyVolunteers":12,"sex":144,"minAge":4,"maxAge":4,"enrollmentInfo":496,"targetDuration":4,"studyType":360,"phases":4,"briefSummary":497,"conditions":498,"keywords":499,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":506,"locationsCount":299},"100601758","the-role-of-pole-mutation-in-high-risk-endometrial-cancer-100601758","NCT07114653","The Role of POLE Mutation in High Risk Endometrial Cancer.","Inclusion Criteria:\n\n* women with high-risk for recurrent endometrial cancer\n\nExclusion Criteria:\n\n* Nil",{"count":308,"type":21},"The actual role of POLE mutations in high-risk endometrial cancer is undetermined. The main question it aims to answer is:\n\nWhat is the prevalence of POLE mutations in high-risk endometrial cancer case? What is the impact of POLE mutations in real world high-risk endometrial cancer case?",[30],[118,500],"POLE mutation","2025-08-04",{"date":466,"type":38},{"date":504,"type":21},"2025-09-01",{"date":405,"type":21},{"name":507,"class":206},"Far Eastern Memorial Hospital",{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":4,"eligibilityCriteria":514,"healthyVolunteers":12,"sex":144,"minAge":18,"maxAge":515,"enrollmentInfo":516,"targetDuration":4,"studyType":22,"phases":518,"briefSummary":519,"conditions":520,"keywords":524,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":536,"locationsCount":473},"100596069","comparison-of-two-position-and-four-position-cervical-injection-techniques-for-sentinel-lymph-node-mapping-in-endometrial-cancer-using-methylene-blue-100596069","NCT07040657","Comparison of Two-Position and Four-Position Cervical Injection Techniques for Sentinel Lymph Node Mapping in Endometrial Cancer Using Methylene Blue","Comparison of Two-Point and Four-Point Cervical Injection Techniques Using Methylene Blue for Sentinel Lymph Node Mapping in Endometrial Cancer","Inclusion Criteria:\n\n* Individuals diagnosed with stage I endometrial cancer based on CT and PET-CT imaging.\n* Individuals with a pathologically confirmed diagnosis of stage I endometrial cancer.\n\nExclusion Criteria:\n\nMedical Conditions\n\n* Individuals diagnosed with dementia.\n* Individuals with allergies to methylene blue or iodine.\n* Individuals who have received active treatment for another malignancy within the past five years.\n* Inability to successfully perform PLD (pelvic lymphadenectomy) or history of prior PLD.\n* Women with multiple and confluent lymph nodes identified as positive on FDG-PET\u002FCT (such cases are not considered stage I).\n\nCancer-Related Conditions\n\n* Individuals with clinically or radiologically identified positive lymph nodes or metastatic disease.\n* Individuals with a history of pelvic dissection and\u002For radiation therapy.\n* Individuals with advanced cervical or uterine cancer.\n* Individuals with T3\u002FT4 lesions.\n* Individuals with cervical tumors larger than 2 cm.\n\nOrgan Dysfunction\n\n• Individuals with hepatic dysfunction and a MELD score ≥ 10 and creatinine ≥ 2·0 mg\u002Fdl patients.","75 Years",{"count":517,"type":21},100,[244],"This clinical trial evaluates lymph node mapping in newly diagnosed endometrial cancer patients undergoing surgery. The standard technique uses a 2-point methylene blue cervical injection. The study aims to determine if increasing injection points improves mapping success.",[30,521,522,523],"Endometrial Cancer Stage I","Sentinel Lymph Node","Metastasis",[525,526,527,528],"endometrial neoplasm","methylene blue","metastasis","cervix","2025-06-18",{"date":531,"type":38},"2025-06-27",{"date":533,"type":38},"2025-05-01",{"date":535,"type":21},"2026-11-01",{"name":537,"class":206},"Dokuz Eylul University",{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":542,"acronym":543,"eligibilityCriteria":544,"healthyVolunteers":12,"sex":144,"minAge":18,"maxAge":4,"enrollmentInfo":545,"targetDuration":4,"studyType":360,"phases":4,"briefSummary":547,"conditions":548,"keywords":553,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":567,"locationsCount":299},"100231289","doveegenewise-genomics-diagnosing-ovarian-and-endometrial-cancer-early-using-genomics-100231289","NCT02288676","DOvEEgene\u002FWISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics","DOvEEgene","Case Inclusion:\n\n* Subjects should have suspected or confirmed cancer of the upper genital tract.\n* Participant will undergo surgery for tumour removal.\n\nControl inclusion:\n\n• Subjects should be scheduled to have a hysterectomy, bilateral salpingectomy, with or without bilateral oophorectomy, for presumed benign disease.",{"count":546,"type":21},1200,"This study aims to develop and validate a test for detecting ovarian and endometrial cancers early. It relies on detecting somatic mutations that are associated with these cancers from a uterine pap test. A saliva sample is also collected that acts as an internal control and has the ability to detect deleterious germline mutations associated with common hereditary cancers (such as breast, ovarian, endometrial, colon, and pancreatic cancers). A machine learning classifier is then used to discriminate between cancer and benign disease.",[28,30,151,315,549,289,550,551,552],"Screening","Reduced Mortality","Reduced Morbidity","Early Diagnosis",[554,555,556,557,558,559,560],"genomics","somatic mutations","genetic mutations","high-grade serous cancer","ovarian cancer","endometrial cancer","DNA tagging","2025-06-13",{"date":529,"type":38},{"date":564,"type":38},"2014-01",{"date":566,"type":21},"2026-10",{"name":568,"class":206},"McGill University",{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":4,"eligibilityCriteria":575,"healthyVolunteers":12,"sex":144,"minAge":576,"maxAge":4,"enrollmentInfo":577,"targetDuration":4,"studyType":22,"phases":578,"briefSummary":579,"conditions":580,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":588,"locationsCount":299},"100500360","phase-2-study-of-induction-pd-1-blockade-nivolumab-in-patients-with-surgically-complete-resectable-mismatch-repair-deficient-endometrial-cancer-nivec-100500360","NCT05795244","Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)","A Phase II Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)","Inclusion Criteria:\n\n1. Explicit and voluntary consent to participation in the trial obtained by signing and dating a consent form that clearly and completely describes the purpose, potential risks, and other important issues related to the trial.\n2. Sex: female\n3. Age (at the time of informed consent): 20 years and older\n4. Subjects with histologically-or cytologically-confirmed endometrial cancer or carcinosarcoma(Mixed Mullerian Tumor)\n5. Clinical stage: Stage I - IIIC2 and surgically completely resectable\n6. No evidence of distant metastases\n7. MMRd or MSI-H subtype (defined by either deficient\u002Floss expression of mismatch repair (MMR) proteins MLH1, PMS2, MSH2, MSH6 or microsatellite instability-high (MSI-H) by polymerase chain reaction assay for 5 microsatellite markers)\n8. ECOG Performance Status Score 0 or 1\n9. Patients with a life expectancy of at least 3 months\n10. Patients whose latest laboratory data meet the below criteria within 7 days before first dose. If the date of the laboratory tests at the time of enrollment is not within 7 days before the first dose of the investigational product, testing must be repeated within 7 days before the first dose of the investigational product, and these latest laboratory tests must meet the following criteria. Of note, laboratory data will not be valid if the patient has received a granulocyte colony-stimulating factor (G CSF) or blood transfusion within 14 days before testing.\n\n    * White blood cells ≥2,000\u002Fmm3 and neutrophils ≥1,500\u002Fmm3\n    * Platelets ≥100,000\u002Fmm3\n    * Hemoglobin ≥9.0 g\u002FdL\n    * AST (GOT) and ALT (GPT) ≤3.0-fold the upper limit of normal (ULN) of the study site (or ≤5.0-fold the ULN of the study site in patients with liver metastases)\n    * Total bilirubin ≤1.5-fold the ULN of the study site\n    * Creatinine ≤1.5-fold the ULN of the study site or creatinine clearance (either the measured or estimated value using the Cockcroft-Gault equation) \\>45 mL\u002Fmin\n11. Women of childbearing potential (including women with chemical menopause or no menstruation for other medical reasons)#1 must agree to use contraception#2 from the time of informed consent until 5months or more after the last dose of the investigational product. Also, women must agree not to breastfeed from the time of informed consent until 5 months or more after the last dose of the investigational product.\n\n    * Women of childbearing potential are defined as all women after the onset of menstruation who are not postmenopausal and have not been surgically sterilized (e.g., hysterectomy, bilateral tubal ligation, bilateral oophorectomy). Post-menopause is defined as amenorrhea for ≥12 consecutive months without specific reasons. Women using oral contraceptives, intrauterine devices, or mechanical contraception such as contraceptive barriers are regarded as having childbearing potential.\n    * The subject must consent to use any one of the following methods of contraception: a condom for the subject's partner (male), an intrauterine device (IUD) for female subjects, or skin implantation of a rod contraceptive (Implanon).\n    * Complete sexual abstinence is also acceptable: Sexual abstinence is considered highly effective only if it is defined as abstaining from sexual intercourse with the opposite sex for the entire duration of the trial treatment-related risks. The reliability of sexual abstinence in relation to the duration of the trial needs to be evaluated, and sexual abstinence should be a preferred and routine lifestyle of the subjects.\n\nExclusion Criteria:\n\n1. Patients with multiple primary cancers (with the exception of completely resected basal cell carcinoma, stage I squamous cell carcinoma, carcinoma in situ, intramucosal carcinoma, or superficial bladder cancer, or any other cancer that has not recurred for at least 5 years)\n2. Patients with residual adverse effects of prior therapy or effects of surgery that would affect the safety evaluation of the investigational product in the opinion of the investigator or sub-investigator.\n3. Patients with current or past history of severe hypersensitivity to any other antibody products\n4. Patients with concurrent autoimmune disease or history of chronic or recurrent autoimmune disease\n5. Patients with a current or past history of interstitial lung disease or pulmonary fibrosis diagnosed based on imaging or clinical findings. Patients with radiation pneumonitis may be randomized if the radiation pneumonitis has been confirmed as stable (beyond acute phase) without any concerns about recurrence.\n6. Patients with concurrent diverticulitis or symptomatic gastrointestinal ulcerative disease\n7. Patients with pericardial fluid, pleural effusion, or ascites requiring treatment\n8. Patients with uncontrollable, tumor-related pain\n9. Patients who have experienced a transient ischemic attack, cerebrovascular accident, thrombosis, or thromboembolism (pulmonary arterial embolism or deep vein thrombosis) within 180 days before randomization\n10. Patients with a history of uncontrollable or significant cardiovascular disease meeting any of the following criteria:\n\n    * Myocardial infarction within 180 days before randomization\n    * Uncontrollable angina pectoris within 180 days before randomization\n    * New York Heart Association (NYHA) Class III or IV congestive heart failure\n    * Uncontrollable hypertension despite appropriate treatment (e.g., systolic blood pressure ≥150mmHg or diastolic blood pressure ≥ 90 mmHg lasting 24 hours or more)\n    * Arrhythmia requiring treatment\n11. Patients receiving or requiring anticoagulant therapy for a disease. Patients receiving antiplatelet therapy including low-dose aspirin may be enrolled.\n12. Patients with uncontrollable diabetes mellitus\n13. Patients with systemic infections requiring treatment\n14. Patients who have received systemic corticosteroids (except for temporary use, e.g., for examination or prophylaxis of allergic reactions) or immunosuppressants within 28 days before randomization\n15. Patients who have received antineoplastic drugs (e.g., chemotherapy agents, molecular-targeted therapy agents, or immunotherapy agents) within 28 days before randomization\n16. Patients who have undergone surgical adhesion of the pleura or pericardium within 28 days before randomization\n17. Patients who have undergone surgery under general anesthesia within 28 days before randomization\n18. Patients who have undergone surgery involving local or topical anesthesia within 14 days before randomization\n19. Patients who have received radiotherapy within 28 days before randomization, or radiotherapy to bone metastases within 14 days before randomization\n20. Patients who have received any radiopharmaceuticals (except for examination or diagnostic use of radiopharmaceuticals) within 56 days before randomization\n21. Patients with a positive test result for any of the following: HIV-1 antibody, HIV-2 antibody, HTLV-1 antibody, HBs antigen, or HCV antibody\n22. Patients with a negative HBs antigen test but a positive test result for either HBs antibody or HBc antibody with a detectable level of HBV-DNA\n23. Women who are pregnant or breastfeeding, or possibly pregnant\n24. Patients who have received any other unapproved drug (e.g., investigational use of drugs, unapproved combined formulations, or unapproved dosage forms) within 28 days before randomization\n25. Patients who have previously received Nivolumab, anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD L2 antibody, anti-CD137 antibody, anti-CTLA-4 antibody or other therapeutic antibodies or pharmacotherapies for regulation of T-cells\n26. Patients judged to be incapable of providing consent for reasons such as concurrent dementia\n27. Other patients judged by the investigator or sub-investigator to be inappropriate as subjects of this study\n28. Patient with current or past history of hypersensitivity to Nivolumab.\n29. WOCBP who has a positive urine pregnancy test within 72 hours prior to allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.","20 Years",{"count":273,"type":21},[25],"phase 2 clinical trial to confirm the pathological complete response rate of PD-1 blocker use in patients with Mismatch Repair Deficiency(MMRd) endometrial cancer that can be completely resected surgically.",[30,151],"2025-05-07",{"date":583,"type":38},"2025-05-13",{"date":585,"type":38},"2023-10-31",{"date":587,"type":21},"2029-12",{"name":231,"class":206},{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":595,"eligibilityCriteria":596,"healthyVolunteers":12,"sex":144,"minAge":597,"maxAge":4,"enrollmentInfo":598,"targetDuration":4,"studyType":22,"phases":600,"briefSummary":601,"conditions":602,"keywords":605,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":609,"startDateStruct":611,"completionDateStruct":613,"leadSponsor":615,"locationsCount":616},"100554719","phase-2-first-line-carboplatin-and-paclitaxel-in-combination-with-pembrolizumab-followed-by-maintenance-pembrolizumab-with-or-without-nesuparib-in-patients-with-newly-diagnosed-advanced-or-recurrent-mmr-proficient-pmmr-endometrial-cancer-100554719","NCT06502743","First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer","Phase 2 Study of First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer","PENELOPE","Inclusion Criteria:\n\n1. Patient must be female ≥ 19 years of age\n2. Histologic confirmation of the original primary tumor is required. Patients with the following histologic types are eligible: Endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, carcinosarcoma, adenocarcinoma not otherwise specified (N.O.S.).\n3. Measurable stage III, measurable stage IVA, stage IVB (with or without measurable disease) or recurrent (with or without measurable disease) endometrial cancer.\n4. MMR proficient confirmed by institutional (local) MMR IHC testing.\n5. Patient must provide the institutional (local) P53 IHC result.\n6. Prior Therapy;\n\n   * Naïve to first line systemic anti-cancer treatment. For patients with recurrent disease only, prior systemic anti-cancer treatment is allowed only if provided adjuvant chemotherapy was completed ≥ 12 months prior to randomization.\n\n     a. Note : For Part A(Safety lead in phase), patient who used Paclitaxel, Carboplatin and Pembrolizumab for first line systemic therapy can participate if they meet all of the following conditions. Patient must have had 6 cycles of chemotherapy; patient must have physician assessed stable disease (SD), partial response (PR), or complete response (CR) after 6 cycles of therapy and patient must be enrolled within 9 weeks of their last dose of chemotherapy (last dose is the day of the last infusion)\n   * Patients may have received prior radiation therapy for treatment of endometrial cancer. Prior radiation therapy may have included pelvic radiation therapy, extended field pelvic\u002Fpara-aortic radiation therapy, and\u002For intravaginal brachytherapy. All radiation therapy must be completed at least 4 weeks prior to randomization.\n   * Patients may have received prior hormonal therapy for treatment of endometrial cancer. All hormonal therapy must be discontinued at least three weeks prior to randomization.\n7. Archival tumor tissue available or a fresh biopsy must be obtained prior to randomization.\n8. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2\n9. Have adequate organ function. Specimens must be collected within 7days prior to the start of study intervention.\n\n   \\- Hematology Absolute neutrophil count (ANC) ≥1,500\u002FμL without growth factor support within 2 weeks before screening test.\n\n   Platelet ≥100,000\u002FμL without transfusion within 2 weeks prior to screening test.\n\n   Hemoglobin ≥10.0 g\u002FdL without transfusion within 2 weeks prior to screening test.\n   * Kidney function Creatinine or measured or calculated creatinine clearance (GFR may also be used in place of creatinine or CrCl a) ≤1.5 × ULN or ≥30 mL\u002Fmin for subjects with creatinine levels \\>1.5 × institutional ULN.\n   * liver function Total bilirubin ≤1.5×ULN or direct bilirubin ≤ULN for subjects whose total bilirubin exceeds 1.5 times the normal value.\n\n   AST (SGOT) and ALT (SGPT) ≤3 × ULN (≤5 × ULN in subjects with liver metastases)\n   * Coagulation International normalized ratio (INR) or prothrombin time (PT) Activated partial thromboplastin time (aPTT) ≤1.5\n   * Thyroid function Thyroid stimulating hormone (TSH) within normal limits (WNL); In euthyroid subjects receiving thyroid replacement therapy, TSH \\\u003C ULN; If an abnormal TSH result is shown, free T4 is normal, and glandular function (euthyroid) is clinically normal, registration is possible.\n10. Patient has voluntarily agreed to participate by giving written informed consent\u002Fassent for the trial.\n11. Women of childbearing potential (WOCBP) must agree to use adequate contraception (hormonal method or abstinence, contraceptive procedure (IUD, Mirena, etc.)) from up to 14 days prior to randomization (for oral contraceptives), during treatment, and for 6 months after the last dose of Paclitaxel + Carboplatin, for 4 months after the last dose of Pembrolizumab, for 3 months after the last dose of Nesuparib, whichever occurs last.\n12. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. Patients will be considered of nonreproductive potential if they are either:\n\n    * Postmenopausal (defined as at least 12 months with no menses without an alternative medical cause; in women \\\u003C45 years of age, a high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient); OR\n    * Have a hysterectomy and\u002For bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation\u002Focclusion, at least 6 weeks prior to randomization; OR Have a congenital or acquired condition that prevents childbearing.\n\nExclusion Criteria:\n\n1. Patient has undergone prior treatment with a known PARP inhibitor.\n2. Patient has a known hypersensitivity to nesuparib, pembrolizumab or combination cytotoxic chemotherapy components or excipients.\n3. MMR deficiency confirmed by institutional MMR IHC testing.\n4. Patients who are currently participating and receiving cancer-directed study therapy or have participated in a study of an investigational agent and received cancer-directed study therapy within 4 weeks prior to randomization.\n5. Patient has known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis. Patients with treated brain metastases may be eligible if follow-up brain imaging after CNS directed therapy shows no evidence of progression, and they have been off steroids for at least 4 weeks prior to randomization and remain clinically stable.\n6. Patient has a known additional malignancy that progressed or required active treatment within the last 2 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer.\n7. Patient has received a live vaccine or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.\n8. Patient has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to randomization.\n\n   * Patients who have received steroids as CT scan contrast premedication may be enrolled.\n   * The use of inhaled or topical corticosteroids is allowed.\n   * The use of mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.\n   * The use of physiologic doses of corticosteroids may be approved after consultation with the study chair.\n9. Patients who have a history of (non-infectious) pneumonitis that required steroids, or current pneumonitis.\n10. Patient with uncontrolled intercurrent illness including, but not limited to: ongoing or active infection (except for uncomplicated urinary tract infection), interstitial lung disease or active, noninfectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n11. Patient has a known history of human immunodeficiency virus (HIV) (HIV 1\u002F2 antibodies)\n12. History of Hepatitis B (defined as HBsAg reactive) or known active Hepatitis C virus (defined as detectable HCV RNA \\[qualitative\\]) infection. Note: Testing for Hepatitis B or C is not required unless mandated by local health authority.\n13. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.\n14. Patient has known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).\n15. Patients with systemic autoimmune disease such as Systemic Lupus Erythematosus.\n16. Has not adequately recovered from major surgery or has ongoing surgical complications.\n17. Has a history or current evidence of any condition, therapy, or laboratory abnormality or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator.\n18. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n19. Is pregnant or breastfeeding or expecting to be pregnant or conceive children within the projected duration of the study, starting with the screening visit through 6 months after the last dose of Paclitaxel + Carboplatin, 4 months after the last dose of Pembrolizumab, 3 months after the last dose of Nesuparib, whichever occurs last.\n20. Has had an allogenic tissue\u002Fsolid organ transplant.","19 Years",{"count":599,"type":21},92,[25],"The goal of this study is listed below.\n\nPart A (Safety Run-in Phase) : To determine feasibility of pembrolizumab and nesuparib combination as maintenance therapy in patients with MMR-proficient advanced and recurrent endometrial cancer. Feasibility is defined as a dose-limiting toxicity (DLT) rate less than or equal to 33%.\n\nPart B (Randomization Phase)\n\n: To evaluate the efficacy of pembrolizumab and nesuparib combination\u002F pembrolizumab monotherapy as maintenance therapy in patients with MMR-proficient advanced stage and recurrent endometrial cancer. Efficacy will be assessed by investigator assessed progression free survival (PFS) as assessed by RECIST 1.1.",[151,153,603,604,30],"Endometrial Carcinoma","Gynecologycal Cancer",[606,156,607],"Nesuparib","MMR-proficient","2025-03-30",{"date":610,"type":38},"2025-04-03",{"date":612,"type":38},"2024-09-12",{"date":614,"type":21},"2027-12",{"name":231,"class":206},6,{"id":618,"slug":619,"hasResults":12,"nctId":620,"briefTitle":621,"officialTitle":622,"acronym":623,"eligibilityCriteria":624,"healthyVolunteers":12,"sex":144,"minAge":18,"maxAge":515,"enrollmentInfo":625,"targetDuration":4,"studyType":22,"phases":627,"briefSummary":628,"conditions":629,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":634,"startDateStruct":636,"completionDateStruct":638,"leadSponsor":640,"locationsCount":299},"100514169","robotic-assisted-versus-conventional-laparoscopic-surgery-in-obese-patients-with-early-endometrial-cancer-100514169","NCT05974995","Robotic-assisted Versus Conventional Laparoscopic Surgery in Obese Patients With Early Endometrial Cancer","Robotic-assisted Versus Conventional Laparoscopic Surgery in the Management of Obese Patients With Early Endometrial Cancer in the Sentinel Lymph Node Era: a Randomized Controlled Study","RObese","Inclusion Criteria:\n\n* BMI \\>=30\n* Age \\> 18\n* Histologically confirmed endometrioid endometrial cancer\n* Clinical early stage (stage I)\n* No contraindication for minimally invasive surgery\n* ASA\\\u003C4\n* Written informed consent.\n\nExclusion Criteria:\n\n* High probability of laparotomy related to uterine volume (US estimated weight \\>250 g)\n* Concomitant pelvic disease, or anatomical characteristics of the patient\n* (Use of uterine manipulator)\n* Age \\>75 years",{"count":626,"type":21},566,[244],"Data across literature suggest that robotic surgery may offer benefit specifically in patient with morbid obesity with endometrial cancer, but to date no randomized trials have been conducted to confirm these observations.\n\nThis randomized controlled multicentric trial aims to evaluate the most appropriate minimally invasive surgical approach in morbidly obese (BMI \\>= 30) patients with endometrial carcinoma.",[151,30,630,631,632],"Obesity, Morbid","Gynecologic Cancer","Gynecologic Disease","2024-10-01",{"date":635,"type":38},"2024-10-03",{"date":637,"type":38},"2023-09-01",{"date":639,"type":21},"2029-09-01",{"name":641,"class":206},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":643,"slug":644,"hasResults":12,"nctId":645,"briefTitle":646,"officialTitle":646,"acronym":4,"eligibilityCriteria":647,"healthyVolunteers":12,"sex":144,"minAge":18,"maxAge":4,"enrollmentInfo":648,"targetDuration":4,"studyType":360,"phases":4,"briefSummary":650,"conditions":651,"keywords":655,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":658,"lastUpdatePostDateStruct":659,"startDateStruct":661,"completionDateStruct":663,"leadSponsor":665,"locationsCount":4},"100556176","translational-study-of-mss-tp53-mutation-and-chromosome-instability-relationship-in-endometrial-carcinoma-100556176","NCT06521684","Translational Study of MSS, TP53 Mutation and Chromosome Instability Relationship in Endometrial Carcinoma","Inclusion Criteria:\n\n* willing to participate in the study and sign the informed consent\n* age ≥18 years old\n* researchers evaluated that it was suitable to participate in this translational study\n* Endometrial cancer was confirmed histologically\n* histopathological molecular classification was consistent with pMMR type and POLE wild type\n* The tumor tissue obtained by operation was the primary lesion\n\nExclusion Criteria:\n\n* Received chemotherapy within 14 days prior to sample collection, or received anti-tumor drug therapy such as radiotherapy, biotherapy, endocrine therapy, targeted therapy, immunotherapy, within 21 days prior to sample collection\n* previously treated with KIF18A inhibitors\n* researchers believed that the subjects were not suitable for the translational study for other reasons",{"count":649,"type":21},110,"The objective is to understand the relationship between TP53 mutation, MSS and chromosome instability in endometrial cancer and the effect on clinical prognosis.We will collect a small amount of tumor tissue samples. NGS panel detection and WGD\u002FAS analysis were performed on the tissue. Paracancer tissue was used as a negative control and relevant information in medical records during the operation. Then we will collect clinical diagnosis and disease information through telephone follow-up after the completion of the operation.",[30,652,653,654],"TP53 Gene Mutation","Chromosomal Instability","Microsatellite Stable Endometrial Carcinoma",[151,653,656,652,657],"microsatellite stability","Whole genome duplication","2024-07-22",{"date":660,"type":38},"2024-07-26",{"date":662,"type":21},"2024-09-01",{"date":664,"type":21},"2025-06-01",{"name":407,"class":206},{"id":667,"slug":668,"hasResults":12,"nctId":669,"briefTitle":670,"officialTitle":671,"acronym":4,"eligibilityCriteria":672,"healthyVolunteers":12,"sex":144,"minAge":18,"maxAge":4,"enrollmentInfo":673,"targetDuration":4,"studyType":22,"phases":675,"briefSummary":676,"conditions":677,"keywords":678,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":681,"lastUpdatePostDateStruct":682,"startDateStruct":684,"completionDateStruct":686,"leadSponsor":688,"locationsCount":263},"100544040","tislelizumab-in-combination-with-chemotherapy-as-a-neoadjuvant-treatment-for-advanced-endometrial-cancer-100544040","NCT06363708","Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer","Tislelizumab Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Endometrial Cancer : A Prospective, Single-arm, Open-label Clinical Study","Inclusion Criteria:\n\n1. Voluntary participation and signed informed consent form;\n2. Age ≥18 years;\n3. Eastern Cooperative Oncology Group performance status 0-1;\n4. The International Federation of Gynecology and Obstetrics (FIGO 2023) stage III-IVb of endometrial cancer;\n5. Has not received any systematic anti-tumor treatment for advanced diseases in the past;\n6. Have measurable disease according to RECIST v1.1 criteria;\n7. Patients must meet the following criteria for laboratory tests to ensure adequate organ function:\n\n   * ANC ≥1,500\u002Fmm3, or ≥1.5×109\u002FL\n   * Platelet count≥75,000\u002Fmm3 or 75 x 109\u002FL\n   * Hemoglobin≥9 g\u002FdL or ≥5.6 mmol\u002FL\n   * Glomerular filtration rate estimated（eGFR） according to the Chronic Kidney Disease Epidemiology Collaborative Group formula （CKD-EPI EQ6）was≥40 mL\u002F 1.73m2\n   * Serum total bilirubin ≤ 1.5x upper limit of normal range（ULN）\n   * Both AST and ALT were ≤3 x ULN\n8. The expected lifespan exceeds 3 months.\n\nExclusion Criteria:\n\n1. Received PD-1 target therapy other than tislelizumab or other antibody or drug therapy that specifically targets T-cell costimulation or checkpoint channels within 6 months before enrollment；\n2. Has human immunodeficiency virus infection, active viral hepatitis, and active tuberculosis infection；\n3. Active leptomeningeal disease or uncontrolled, untreated brain metastases resulting in elevated intracranial pressure;\n4. Major surgical procedures had been performed within 4 weeks before consent was obtained；\n5. Other conditions deemed by the investigator to be ineligible for enrollment.",{"count":674,"type":21},20,[244],"The goal of this clinical trial is to evaluate the efficacy and safety of tislelizumab in combination with chemotherapy as a neoadjuvant treatment for advanced endometrial cancer.",[30],[679,151,680],"Oncology","Tislelizumab","2024-04-11",{"date":683,"type":38},"2024-04-12",{"date":685,"type":21},"2024-06-01",{"date":687,"type":21},"2026-06-30",{"name":689,"class":206},"Zhongnan Hospital",{"id":691,"slug":692,"hasResults":12,"nctId":693,"briefTitle":694,"officialTitle":695,"acronym":4,"eligibilityCriteria":696,"healthyVolunteers":12,"sex":144,"minAge":18,"maxAge":271,"enrollmentInfo":697,"targetDuration":4,"studyType":360,"phases":4,"briefSummary":699,"conditions":700,"keywords":701,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":706,"lastUpdatePostDateStruct":707,"startDateStruct":709,"completionDateStruct":711,"leadSponsor":713,"locationsCount":299},"100525796","mri-radiomics-combined-with-pathomics-on-the-prediction-of-molecular-classification-and-prognosis-of-endometrial-cancer-100525796","NCT06126393","MRI Radiomics Combined With Pathomics on the Prediction of Molecular Classification and Prognosis of Endometrial Cancer","Study on the Prediction of Molecular Classification and Prognosis of Endometrial Cancer Using a Model Constructed by Magnetic Resonance Imaging Radiomics Combined With Pathomics","Inclusion Criteria:\n\n* •Pathologically confirmed as endometrial malignant tumor with complete pathological H＆E stained sections;\n\n  * Age ≥ 18 years and ≤ 80 years;\n  * No other malignant cancers was found;\n  * The complete immunohistochemical and second-generation sequencing results can be used for the molecular typing of ProMisE;\n  * Magnetic resonance examination was performed within 2 weeks before treatment, and there was at least one measurable lesion according to RECIST 1.1 Criteria.\n\nExclusion Criteria:\n\n* • The image quality is poor or the tumor is too small due to serious graphic artifact and degeneration, and the ROI cannot be accurately delineated;\n\n  * Patients who received any antitumor therapy before surgery;\n  * Diagnostic endometrial biopsy before MRI",{"count":698,"type":21},350,"Molecular typing provides accurate information for the diagnosis, treatment and prognosis prediction of endometrial cancer, which has important clinical significance. However, due to its high cost and complicated process, it is difficult to be widely used in clinical practice. Based on the artificial intelligence method, this study fused the characteristics of MRI radiomics and pathomics, combined with the clinical pathological information, built a model to predict the molecular typing and prognosis, analyzed the biological characteristics of endometrial cancer from the multi-scale level, guided the personalized and precise diagnosis and treatment, in order to improve the prognosis of patients.",[30],[30,702,703,704,705],"machine learning","Radiomics","Pathomics","TCGA classification","2023-11-13",{"date":708,"type":38},"2023-11-15",{"date":710,"type":21},"2024-01-01",{"date":712,"type":21},"2027-06-30",{"name":714,"class":715},"Fujian Cancer Hospital","OTHER_GOV",{"id":717,"slug":718,"hasResults":12,"nctId":719,"briefTitle":720,"officialTitle":721,"acronym":4,"eligibilityCriteria":722,"healthyVolunteers":12,"sex":144,"minAge":18,"maxAge":456,"enrollmentInfo":723,"targetDuration":4,"studyType":22,"phases":725,"briefSummary":726,"conditions":727,"keywords":732,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":736,"lastUpdatePostDateStruct":737,"startDateStruct":739,"completionDateStruct":741,"leadSponsor":743,"locationsCount":299},"100511896","fertility-sparing-therapy-for-patients-with-stage-ia-endometrial-cancer-100511896","NCT05945407","Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer","Establishment of a Network Platform for Fertility-sparing in Patients With Endometrial Cancer and Study on Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer.","Inclusion Criteria:\n\n* Stage IA (FIGO 2009) ;\n* Pathological diagnosis: endometrial adenocarcinoma G1-G2;\n* MRI or ultrasound: tumor limited to endometrium or invading less than 1\u002F2 of myometrium；\n* 18 years old ≤ Age ≤ 45 years old;\n* With a strong desire for fertility preservation；\n* Sign the informed consent.\n\nExclusion Criteria:\n\n* Complicated with any other malignancy；\n* Contraindications to conservative treatment；\n* Contraindications to progestin use;\n* Contraindications to pregnancy, or judged by the researcher to be unfit for pregnancy or delivery.",{"count":724,"type":21},57,[244],"The goal of this clinical trial is to explore the feasibility and outcome of fertility-sparing therapy in Stage IA G1-G2 Endometrial Cancer with less than 1\u002F2 myometrial invasion. Researchers will render participants indication-extended fertility-sparing therapy. Researchers will compare the myometrial invasion group with the no myometrial invasion group to see if it is possible to propose an extension indication of fertility-sparing therapy for endometrial cancer.",[30,728,729,730,731],"Endometrial Neoplasm Malignant","Endometrial Neoplasm Malignant Stage I","Carcinoma, Endometrioid","Fertility Preservation",[733,734,603,151,735],"Fertility-sparing","Fertility-preserving","Indication Extension","2023-07-12",{"date":738,"type":38},"2023-07-14",{"date":740,"type":38},"2016-08-01",{"date":742,"type":21},"2027-12-31",{"name":744,"class":206},"Peking University People's Hospital"]